US20180245154A1 - Methods to diagnose and treat acute respiratory infections - Google Patents
Methods to diagnose and treat acute respiratory infections Download PDFInfo
- Publication number
- US20180245154A1 US20180245154A1 US15/738,339 US201615738339A US2018245154A1 US 20180245154 A1 US20180245154 A1 US 20180245154A1 US 201615738339 A US201615738339 A US 201615738339A US 2018245154 A1 US2018245154 A1 US 2018245154A1
- Authority
- US
- United States
- Prior art keywords
- classifier
- ari
- bacterial
- viral
- infectious
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 127
- 230000001154 acute effect Effects 0.000 title claims abstract description 83
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 49
- 239000012472 biological sample Substances 0.000 claims abstract description 61
- 230000001580 bacterial effect Effects 0.000 claims description 247
- 208000015181 infectious disease Diseases 0.000 claims description 236
- 230000003612 virological effect Effects 0.000 claims description 232
- 108090000623 proteins and genes Proteins 0.000 claims description 215
- 230000014509 gene expression Effects 0.000 claims description 177
- 230000002458 infectious effect Effects 0.000 claims description 173
- 239000000523 sample Substances 0.000 claims description 150
- 230000000241 respiratory effect Effects 0.000 claims description 45
- 230000004044 response Effects 0.000 claims description 39
- 238000001514 detection method Methods 0.000 claims description 32
- 238000005259 measurement Methods 0.000 claims description 32
- 208000024891 symptom Diseases 0.000 claims description 31
- 238000003860 storage Methods 0.000 claims description 28
- 208000035143 Bacterial infection Diseases 0.000 claims description 24
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 24
- 238000004458 analytical method Methods 0.000 claims description 21
- 208000036142 Viral infection Diseases 0.000 claims description 20
- 238000003753 real-time PCR Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 230000009385 viral infection Effects 0.000 claims description 16
- 238000009396 hybridization Methods 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims description 9
- 239000011886 peripheral blood Substances 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000002751 oligonucleotide probe Substances 0.000 claims description 7
- 238000004949 mass spectrometry Methods 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 238000011269 treatment regimen Methods 0.000 claims description 6
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- 238000012417 linear regression Methods 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 230000001186 cumulative effect Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 229940124350 antibacterial drug Drugs 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 54
- 238000012360 testing method Methods 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 30
- 238000012549 training Methods 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- 241000700605 Viruses Species 0.000 description 25
- 241000894006 Bacteria Species 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 22
- 238000002493 microarray Methods 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 20
- 244000052769 pathogen Species 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 206010022000 influenza Diseases 0.000 description 17
- 238000011002 quantification Methods 0.000 description 16
- 244000052613 viral pathogen Species 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 102100034237 Endosome/lysosome-associated apoptosis and autophagy regulator 1 Human genes 0.000 description 14
- 101000925880 Homo sapiens Endosome/lysosome-associated apoptosis and autophagy regulator 1 Proteins 0.000 description 14
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 13
- 101000998629 Homo sapiens Importin subunit beta-1 Proteins 0.000 description 13
- 102100033258 Importin subunit beta-1 Human genes 0.000 description 13
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000001717 pathogenic effect Effects 0.000 description 13
- 101000946040 Homo sapiens Lysosomal-associated transmembrane protein 4B Proteins 0.000 description 12
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 12
- 102100034726 Lysosomal-associated transmembrane protein 4B Human genes 0.000 description 12
- 206010035664 Pneumonia Diseases 0.000 description 12
- 206010040047 Sepsis Diseases 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 11
- 101000830568 Homo sapiens Tumor necrosis factor alpha-induced protein 2 Proteins 0.000 description 11
- 102100032931 Peroxisome assembly factor 2 Human genes 0.000 description 11
- 238000011529 RT qPCR Methods 0.000 description 11
- 102100024868 SH3 domain-binding protein 1 Human genes 0.000 description 11
- 102100024595 Tumor necrosis factor alpha-induced protein 2 Human genes 0.000 description 11
- 230000034994 death Effects 0.000 description 11
- 231100000517 death Toxicity 0.000 description 11
- 238000007477 logistic regression Methods 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 102100035473 2'-5'-oligoadenylate synthase-like protein Human genes 0.000 description 10
- 102100034487 28S ribosomal protein S18b, mitochondrial Human genes 0.000 description 10
- 102100037710 40S ribosomal protein S21 Human genes 0.000 description 10
- 102100040038 Amyloid beta precursor like protein 2 Human genes 0.000 description 10
- 102100024263 CD160 antigen Human genes 0.000 description 10
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 10
- 102100032636 Copine-1 Human genes 0.000 description 10
- 102100039540 Exocyst complex component 7 Human genes 0.000 description 10
- 102100039632 Glioma pathogenesis-related protein 1 Human genes 0.000 description 10
- 102100034009 Glutamate dehydrogenase 1, mitochondrial Human genes 0.000 description 10
- 101000597360 Homo sapiens 2'-5'-oligoadenylate synthase-like protein Proteins 0.000 description 10
- 101000639839 Homo sapiens 28S ribosomal protein S18b, mitochondrial Proteins 0.000 description 10
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 10
- 101000888759 Homo sapiens Glioma pathogenesis-related protein 1 Proteins 0.000 description 10
- 102100035878 Krev interaction trapped protein 1 Human genes 0.000 description 10
- 102100021762 Phosphoserine phosphatase Human genes 0.000 description 10
- 108010048233 Procalcitonin Proteins 0.000 description 10
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 10
- 102100026043 Transcription factor BTF3 Human genes 0.000 description 10
- 102100025755 Transmembrane protein 165 Human genes 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 10
- 102100037094 cGMP-inhibited 3',5'-cyclic phosphodiesterase B Human genes 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 9
- 102100021660 60S ribosomal protein L28 Human genes 0.000 description 9
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 9
- 102100021390 C-terminal-binding protein 1 Human genes 0.000 description 9
- 102100032912 CD44 antigen Human genes 0.000 description 9
- 102100033086 Calcium/calmodulin-dependent protein kinase type 1 Human genes 0.000 description 9
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 9
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 9
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 9
- 102100026680 Chromobox protein homolog 7 Human genes 0.000 description 9
- 208000003322 Coinfection Diseases 0.000 description 9
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 9
- 102100023348 DNA-directed RNA polymerases I, II, and III subunit RPABC2 Human genes 0.000 description 9
- 102000005721 Death-Associated Protein Kinases Human genes 0.000 description 9
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 description 9
- 102100040481 Desmocollin-2 Human genes 0.000 description 9
- 102100038415 ELKS/Rab6-interacting/CAST family member 1 Human genes 0.000 description 9
- 102100035786 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 Human genes 0.000 description 9
- 102100030493 HEAT repeat-containing protein 1 Human genes 0.000 description 9
- 108700005087 Homeobox Genes Proteins 0.000 description 9
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 description 9
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 9
- 101000910835 Homo sapiens Chromobox protein homolog 7 Proteins 0.000 description 9
- 101000686009 Homo sapiens DNA-directed RNA polymerases I, II, and III subunit RPABC2 Proteins 0.000 description 9
- 101001073247 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 Proteins 0.000 description 9
- 101000990572 Homo sapiens HEAT repeat-containing protein 1 Proteins 0.000 description 9
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 description 9
- 101000975401 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 3 Proteins 0.000 description 9
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 9
- 101000701614 Homo sapiens Nuclear autoantigen Sp-100 Proteins 0.000 description 9
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 9
- 101000872514 Homo sapiens Probable E3 ubiquitin-protein ligase HERC1 Proteins 0.000 description 9
- 101000693903 Homo sapiens S phase cyclin A-associated protein in the endoplasmic reticulum Proteins 0.000 description 9
- 101000629594 Homo sapiens S1 RNA-binding domain-containing protein 1 Proteins 0.000 description 9
- 101000880124 Homo sapiens SERTA domain-containing protein 3 Proteins 0.000 description 9
- 101000648042 Homo sapiens Signal-transducing adaptor protein 1 Proteins 0.000 description 9
- 101000652707 Homo sapiens Transcription initiation factor TFIID subunit 4 Proteins 0.000 description 9
- 101000765926 Homo sapiens tRNA:m(4)X modification enzyme TRM13 homolog Proteins 0.000 description 9
- 102100024035 Inositol 1,4,5-trisphosphate receptor type 3 Human genes 0.000 description 9
- 102100037874 Intercellular adhesion molecule 4 Human genes 0.000 description 9
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 description 9
- 102100021416 Myotubularin-related protein 1 Human genes 0.000 description 9
- 102100027894 Ninjurin-1 Human genes 0.000 description 9
- 102100030436 Nuclear autoantigen Sp-100 Human genes 0.000 description 9
- 102100028467 Perforin-1 Human genes 0.000 description 9
- 102100034747 Probable E3 ubiquitin-protein ligase HERC1 Human genes 0.000 description 9
- 102100027663 Rho GTPase-activating protein 12 Human genes 0.000 description 9
- 102100027219 S phase cyclin A-associated protein in the endoplasmic reticulum Human genes 0.000 description 9
- 102100026836 S1 RNA-binding domain-containing protein 1 Human genes 0.000 description 9
- 102100037366 SERTA domain-containing protein 3 Human genes 0.000 description 9
- 102100025263 Signal-transducing adaptor protein 1 Human genes 0.000 description 9
- 102100035115 Testin Human genes 0.000 description 9
- 102100034707 Thiosulfate sulfurtransferase Human genes 0.000 description 9
- 102100030833 Transcription initiation factor TFIID subunit 4 Human genes 0.000 description 9
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 9
- 238000003491 array Methods 0.000 description 9
- 244000052616 bacterial pathogen Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000004590 computer program Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 9
- 102100026593 tRNA:m(4)X modification enzyme TRM13 homolog Human genes 0.000 description 9
- 102100021408 14-3-3 protein beta/alpha Human genes 0.000 description 8
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 description 8
- 102100033889 Actin-related protein 2/3 complex subunit 3 Human genes 0.000 description 8
- 102100026425 Adhesion G protein-coupled receptor E3 Human genes 0.000 description 8
- 102100034614 Ankyrin repeat domain-containing protein 11 Human genes 0.000 description 8
- 102100023579 Autophagy-related protein 2 homolog A Human genes 0.000 description 8
- 102100032220 Calcium and integrin-binding family member 2 Human genes 0.000 description 8
- 102100025647 Cilia- and flagella-associated protein 45 Human genes 0.000 description 8
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 102100035087 Ectoderm-neural cortex protein 1 Human genes 0.000 description 8
- 102000017177 Fibromodulin Human genes 0.000 description 8
- 108010013996 Fibromodulin Proteins 0.000 description 8
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 8
- 101000818893 Homo sapiens 14-3-3 protein beta/alpha Proteins 0.000 description 8
- 101000718235 Homo sapiens Adhesion G protein-coupled receptor E3 Proteins 0.000 description 8
- 101000890401 Homo sapiens Amyloid beta precursor like protein 2 Proteins 0.000 description 8
- 101000905707 Homo sapiens Autophagy-related protein 2 homolog A Proteins 0.000 description 8
- 101000914176 Homo sapiens Cilia- and flagella-associated protein 45 Proteins 0.000 description 8
- 101000877456 Homo sapiens Ectoderm-neural cortex protein 1 Proteins 0.000 description 8
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 8
- 101001039757 Homo sapiens Multiple C2 and transmembrane domain-containing protein 1 Proteins 0.000 description 8
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 8
- 101000657350 Homo sapiens RNA-splicing ligase RtcB homolog Proteins 0.000 description 8
- 101000761651 Homo sapiens SH3 domain-binding protein 1 Proteins 0.000 description 8
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 description 8
- 101000595682 Homo sapiens Tubulin beta-1 chain Proteins 0.000 description 8
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 8
- 101001098812 Homo sapiens cGMP-inhibited 3',5'-cyclic phosphodiesterase B Proteins 0.000 description 8
- 108700042464 KRIT1 Proteins 0.000 description 8
- 101150090242 KRIT1 gene Proteins 0.000 description 8
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 8
- 102100040889 Multiple C2 and transmembrane domain-containing protein 1 Human genes 0.000 description 8
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 8
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 8
- 108010047871 Phosphopantothenoyl-cysteine decarboxylase Proteins 0.000 description 8
- 102100033809 Phosphopantothenoylcysteine decarboxylase Human genes 0.000 description 8
- 102100027134 Protein orai-2 Human genes 0.000 description 8
- 102100034776 RNA-splicing ligase RtcB homolog Human genes 0.000 description 8
- 102100032770 Signal-regulatory protein beta-1 isoform 3 Human genes 0.000 description 8
- 102100029970 Sodium/hydrogen exchanger 8 Human genes 0.000 description 8
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 description 8
- 102100036084 Tubulin beta-1 chain Human genes 0.000 description 8
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 8
- 102100024773 Zinc finger protein 335 Human genes 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 238000010200 validation analysis Methods 0.000 description 8
- 102100021403 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial Human genes 0.000 description 7
- 102100025222 CD63 antigen Human genes 0.000 description 7
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 description 7
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 7
- 102100021158 Double homeobox protein 4 Human genes 0.000 description 7
- 102100038509 E3 ubiquitin-protein ligase ARIH1 Human genes 0.000 description 7
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 7
- 102100035143 Folate receptor gamma Human genes 0.000 description 7
- 102100024421 GTPase IMAP family member 6 Human genes 0.000 description 7
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 7
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 7
- 102100023434 Heterogeneous nuclear ribonucleoprotein A0 Human genes 0.000 description 7
- 101001041661 Homo sapiens 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial Proteins 0.000 description 7
- 101001097814 Homo sapiens 40S ribosomal protein S21 Proteins 0.000 description 7
- 101000925574 Homo sapiens Actin-related protein 2/3 complex subunit 3 Proteins 0.000 description 7
- 101000941754 Homo sapiens Copine-1 Proteins 0.000 description 7
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 7
- 101000968549 Homo sapiens Double homeobox protein 4 Proteins 0.000 description 7
- 101000808922 Homo sapiens E3 ubiquitin-protein ligase ARIH1 Proteins 0.000 description 7
- 101000813489 Homo sapiens Exocyst complex component 7 Proteins 0.000 description 7
- 101001023202 Homo sapiens Folate receptor gamma Proteins 0.000 description 7
- 101000833389 Homo sapiens GTPase IMAP family member 6 Proteins 0.000 description 7
- 101000870042 Homo sapiens Glutamate dehydrogenase 1, mitochondrial Proteins 0.000 description 7
- 101000599868 Homo sapiens Intercellular adhesion molecule 4 Proteins 0.000 description 7
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 description 7
- 101000988395 Homo sapiens PDZ and LIM domain protein 4 Proteins 0.000 description 7
- 101000730779 Homo sapiens Peroxisome assembly factor 2 Proteins 0.000 description 7
- 101000615965 Homo sapiens Phosphoserine phosphatase Proteins 0.000 description 7
- 101001062760 Homo sapiens Protein FAM13A Proteins 0.000 description 7
- 101000686656 Homo sapiens Ribonuclease P protein subunit p25 Proteins 0.000 description 7
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 description 7
- 101000800616 Homo sapiens Teneurin-3 Proteins 0.000 description 7
- 101000645421 Homo sapiens Transmembrane protein 165 Proteins 0.000 description 7
- 101000784545 Homo sapiens Zinc finger and SCAN domain-containing protein 18 Proteins 0.000 description 7
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 description 7
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 7
- 102100029178 PDZ and LIM domain protein 4 Human genes 0.000 description 7
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 7
- 102100030557 Protein FAM13A Human genes 0.000 description 7
- 102100024752 Ribonuclease P protein subunit p25 Human genes 0.000 description 7
- 102100032855 Sialoadhesin Human genes 0.000 description 7
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 description 7
- 102100033191 Teneurin-3 Human genes 0.000 description 7
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 7
- 102100032452 Transmembrane protease serine 6 Human genes 0.000 description 7
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 description 7
- 102100020915 Zinc finger and SCAN domain-containing protein 18 Human genes 0.000 description 7
- 238000002790 cross-validation Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 7
- 230000004547 gene signature Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000002345 respiratory system Anatomy 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 102100022908 ADP-ribosylation factor-like protein 1 Human genes 0.000 description 6
- 102100033392 ATP-dependent RNA helicase DDX3Y Human genes 0.000 description 6
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 6
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 6
- 102100036212 Cytochrome P450 2A7 Human genes 0.000 description 6
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 6
- 101710161408 Folylpolyglutamate synthase Proteins 0.000 description 6
- 102100035067 Folylpolyglutamate synthase, mitochondrial Human genes 0.000 description 6
- 101710200122 Folylpolyglutamate synthase, mitochondrial Proteins 0.000 description 6
- 102100033366 Glutathione hydrolase 1 proenzyme Human genes 0.000 description 6
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 description 6
- 102100037487 Histone H1.0 Human genes 0.000 description 6
- 101000676271 Homo sapiens 60S ribosomal protein L28 Proteins 0.000 description 6
- 101000974500 Homo sapiens ADP-ribosylation factor-like protein 1 Proteins 0.000 description 6
- 101000870664 Homo sapiens ATP-dependent RNA helicase DDX3Y Proteins 0.000 description 6
- 101000984916 Homo sapiens Butyrophilin subfamily 3 member A3 Proteins 0.000 description 6
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 6
- 101000944250 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1 Proteins 0.000 description 6
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 6
- 101000968042 Homo sapiens Desmocollin-2 Proteins 0.000 description 6
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 6
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 6
- 101001100208 Homo sapiens ELKS/Rab6-interacting/CAST family member 1 Proteins 0.000 description 6
- 101000997558 Homo sapiens Glutathione hydrolase 1 proenzyme Proteins 0.000 description 6
- 101001011393 Homo sapiens Interferon regulatory factor 2 Proteins 0.000 description 6
- 101000975939 Homo sapiens Kinase D-interacting substrate of 220 kDa Proteins 0.000 description 6
- 101001027796 Homo sapiens Male-specific lethal 1 homolog Proteins 0.000 description 6
- 101000578920 Homo sapiens Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 Proteins 0.000 description 6
- 101000969334 Homo sapiens Myotubularin-related protein 1 Proteins 0.000 description 6
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 description 6
- 101000632154 Homo sapiens Ninjurin-1 Proteins 0.000 description 6
- 101000581155 Homo sapiens Rho GTPase-activating protein 12 Proteins 0.000 description 6
- 101000626125 Homo sapiens Tetranectin Proteins 0.000 description 6
- 101000933542 Homo sapiens Transcription factor BTF3 Proteins 0.000 description 6
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 description 6
- 102100029838 Interferon regulatory factor 2 Human genes 0.000 description 6
- 102100040021 Interferon-induced transmembrane protein 1 Human genes 0.000 description 6
- 102100023924 Kinase D-interacting substrate of 220 kDa Human genes 0.000 description 6
- 102100037714 Male-specific lethal 1 homolog Human genes 0.000 description 6
- 102100028322 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 Human genes 0.000 description 6
- 102100029494 Neutrophil defensin 1 Human genes 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 101710155795 Probable folylpolyglutamate synthase Proteins 0.000 description 6
- 101710151871 Putative folylpolyglutamate synthase Proteins 0.000 description 6
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 6
- 108091006658 SLC9A8 Proteins 0.000 description 6
- 102100026263 Sphingomyelin phosphodiesterase Human genes 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 102100024554 Tetranectin Human genes 0.000 description 6
- 108010022173 Thiosulfate sulfurtransferase Proteins 0.000 description 6
- 102100027654 Transcription factor PU.1 Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 101150118453 ctbp-1 gene Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 108010067667 gamma Subunit Interferon-Stimulated Gene Factor 3 Proteins 0.000 description 6
- 108060003196 globin Proteins 0.000 description 6
- 102000018146 globin Human genes 0.000 description 6
- 238000007403 mPCR Methods 0.000 description 6
- 230000002906 microbiologic effect Effects 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000013610 patient sample Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 102100038451 CDK5 regulatory subunit-associated protein 2 Human genes 0.000 description 5
- 108010055211 EphA1 Receptor Proteins 0.000 description 5
- 101000823089 Equus caballus Alpha-1-antiproteinase 1 Proteins 0.000 description 5
- 102100029956 F-actin-capping protein subunit beta Human genes 0.000 description 5
- 101000924476 Homo sapiens Ankyrin repeat domain-containing protein 11 Proteins 0.000 description 5
- 101000943456 Homo sapiens Calcium and integrin-binding family member 2 Proteins 0.000 description 5
- 101000875173 Homo sapiens Cytochrome P450 2A7 Proteins 0.000 description 5
- 101000793778 Homo sapiens F-actin-capping protein subunit beta Proteins 0.000 description 5
- 101001034844 Homo sapiens Interferon-induced transmembrane protein 1 Proteins 0.000 description 5
- 101000830386 Homo sapiens Neutrophil defensin 3 Proteins 0.000 description 5
- 101000712725 Homo sapiens Ras-related protein Rab-7L1 Proteins 0.000 description 5
- 101000686860 Homo sapiens Reticulophagy regulator 3 Proteins 0.000 description 5
- 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 description 5
- 101000709256 Homo sapiens Signal-regulatory protein beta-1 Proteins 0.000 description 5
- 101000709188 Homo sapiens Signal-regulatory protein beta-1 isoform 3 Proteins 0.000 description 5
- 101000785978 Homo sapiens Sphingomyelin phosphodiesterase Proteins 0.000 description 5
- 101001050297 Homo sapiens Transcription factor JunD Proteins 0.000 description 5
- 101000798696 Homo sapiens Transmembrane protease serine 6 Proteins 0.000 description 5
- 101000760227 Homo sapiens Zinc finger protein 335 Proteins 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 102100024761 Neutrophil defensin 3 Human genes 0.000 description 5
- 108700027852 ORAI2 Proteins 0.000 description 5
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 5
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 5
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 5
- 102100033100 Ras-related protein Rab-7L1 Human genes 0.000 description 5
- 102100024732 Reticulophagy regulator 3 Human genes 0.000 description 5
- 102100023118 Transcription factor JunD Human genes 0.000 description 5
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 229940126836 transmembrane protease serine 6 synthesis reducer Drugs 0.000 description 5
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 description 4
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 description 4
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 description 4
- 102100024419 28S ribosomal protein S31, mitochondrial Human genes 0.000 description 4
- 102100023989 Actin-related protein 2 Human genes 0.000 description 4
- 108090000963 Actin-related protein 2 Proteins 0.000 description 4
- 102100026438 Adhesion G-protein coupled receptor D2 Human genes 0.000 description 4
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 4
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 4
- 101710146894 Basic transcription factor 3 Proteins 0.000 description 4
- 102100025238 CD302 antigen Human genes 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 4
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- 102100038742 Cytochrome P450 2A13 Human genes 0.000 description 4
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 description 4
- 102100039247 ETS-related transcription factor Elf-4 Human genes 0.000 description 4
- 102100021469 Equilibrative nucleoside transporter 1 Human genes 0.000 description 4
- 102100038985 Exosome complex component RRP41 Human genes 0.000 description 4
- 102100040988 Formin-binding protein 4 Human genes 0.000 description 4
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 4
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 4
- 108010061311 HLA-DRB3 Chains Proteins 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 4
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 description 4
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 description 4
- 101000689847 Homo sapiens 28S ribosomal protein S31, mitochondrial Proteins 0.000 description 4
- 101000718223 Homo sapiens Adhesion G-protein coupled receptor D2 Proteins 0.000 description 4
- 101000718041 Homo sapiens Aldo-keto reductase family 1 member B10 Proteins 0.000 description 4
- 101000934351 Homo sapiens CD302 antigen Proteins 0.000 description 4
- 101000882873 Homo sapiens CDK5 regulatory subunit-associated protein 2 Proteins 0.000 description 4
- 101000957389 Homo sapiens Cytochrome P450 2A13 Proteins 0.000 description 4
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 description 4
- 101000813135 Homo sapiens ETS-related transcription factor Elf-4 Proteins 0.000 description 4
- 101000685879 Homo sapiens Heterogeneous nuclear ribonucleoprotein A0 Proteins 0.000 description 4
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 4
- 101001026554 Homo sapiens Histone H1.0 Proteins 0.000 description 4
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 4
- 101000918983 Homo sapiens Neutrophil defensin 1 Proteins 0.000 description 4
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 description 4
- 101000639802 Homo sapiens U2 small nuclear ribonucleoprotein B'' Proteins 0.000 description 4
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 4
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 4
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 4
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 4
- 102100029607 Interferon-induced protein 44 Human genes 0.000 description 4
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 description 4
- 102100027303 Interferon-induced protein with tetratricopeptide repeats 2 Human genes 0.000 description 4
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 description 4
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 4
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 4
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 4
- 102100025533 MTOR-associated protein MEAK7 Human genes 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 101710141834 Peroxisomal biogenesis factor 6 Proteins 0.000 description 4
- 101710205272 Peroxisome assembly factor 2 Proteins 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- 108091006551 SLC29A1 Proteins 0.000 description 4
- 102100032743 Septin-4 Human genes 0.000 description 4
- 241000713880 Spleen focus-forming virus Species 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 4
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 4
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 description 4
- 102100039488 XIAP-associated factor 1 Human genes 0.000 description 4
- -1 antibodies Chemical class 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000009795 derivation Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 102100022048 60S ribosomal protein L36 Human genes 0.000 description 3
- 102100039602 ARF GTPase-activating protein GIT2 Human genes 0.000 description 3
- 102000003741 Actin-related protein 3 Human genes 0.000 description 3
- 108090000104 Actin-related protein 3 Proteins 0.000 description 3
- 101710188804 Ankyrin repeat domain-containing protein 11 Proteins 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 description 3
- 101710178052 C-terminal-binding protein 1 Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 101710160032 Calcium and integrin-binding family member 2 Proteins 0.000 description 3
- 101710200183 Calcium/calmodulin-dependent protein kinase I Proteins 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 101710190844 Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 3
- 101710125095 Copine-1 Proteins 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- 102100024465 Cyclin-dependent kinase 4 inhibitor C Human genes 0.000 description 3
- 102100024463 Cyclin-dependent kinase 4 inhibitor D Human genes 0.000 description 3
- 102100039851 DNA-directed RNA polymerases I and III subunit RPAC1 Human genes 0.000 description 3
- 102000000541 Defensins Human genes 0.000 description 3
- 108010002069 Defensins Proteins 0.000 description 3
- 101710157873 Desmocollin-2 Proteins 0.000 description 3
- 101710180090 ELKS/Rab6-interacting/CAST family member 1 Proteins 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 244000187656 Eucalyptus cornuta Species 0.000 description 3
- 101710170829 Exocyst complex component 7 Proteins 0.000 description 3
- 102100024637 Galectin-10 Human genes 0.000 description 3
- 101710122170 Glutamate dehydrogenase 1 Proteins 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 101710203706 Heterogeneous nuclear ribonucleoprotein A0 Proteins 0.000 description 3
- 101000888642 Homo sapiens ARF GTPase-activating protein GIT2 Proteins 0.000 description 3
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 3
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 description 3
- 101000777564 Homo sapiens C-C chemokine receptor type 1 Proteins 0.000 description 3
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 3
- 101000669166 Homo sapiens DNA-directed RNA polymerases I and III subunit RPAC1 Proteins 0.000 description 3
- 101000882162 Homo sapiens Exosome complex component RRP41 Proteins 0.000 description 3
- 101000892778 Homo sapiens Formin-binding protein 4 Proteins 0.000 description 3
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 description 3
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 description 3
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 description 3
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 description 3
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 description 3
- 101001082058 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 description 3
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 description 3
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 3
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 description 3
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 description 3
- 101000575048 Homo sapiens MTOR-associated protein MEAK7 Proteins 0.000 description 3
- 101000813497 Homo sapiens Nuclease EXOG, mitochondrial Proteins 0.000 description 3
- 101000639063 Homo sapiens Protein UXT Proteins 0.000 description 3
- 101001122470 Homo sapiens Protein orai-2 Proteins 0.000 description 3
- 101000685923 Homo sapiens Protein transport protein Sec24A Proteins 0.000 description 3
- 101000964532 Homo sapiens Protein zer-1 homolog Proteins 0.000 description 3
- 101001077015 Homo sapiens Rab GTPase-activating protein 1-like Proteins 0.000 description 3
- 101001077011 Homo sapiens Rab GTPase-activating protein 1-like, isoform 10 Proteins 0.000 description 3
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 description 3
- 101000828739 Homo sapiens SPATS2-like protein Proteins 0.000 description 3
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 3
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 description 3
- 101000800639 Homo sapiens Teneurin-1 Proteins 0.000 description 3
- 101000596825 Homo sapiens Testin Proteins 0.000 description 3
- 101000802084 Homo sapiens Thiosulfate sulfurtransferase Proteins 0.000 description 3
- 101000847156 Homo sapiens Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 description 3
- 101000814514 Homo sapiens XIAP-associated factor 1 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010021137 Hypovolaemia Diseases 0.000 description 3
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 description 3
- 102000004344 Interferon regulatory factor 2 Human genes 0.000 description 3
- 108090000908 Interferon regulatory factor 2 Proteins 0.000 description 3
- 101710166699 Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 3
- 108010062228 Karyopherins Proteins 0.000 description 3
- 102000011781 Karyopherins Human genes 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 3
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108050002119 Myotubularin-related protein 1 Proteins 0.000 description 3
- 108050006720 Ninjurin1 Proteins 0.000 description 3
- 102100039557 Nuclease EXOG, mitochondrial Human genes 0.000 description 3
- 101150002636 ORAI2 gene Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 102100023368 Protein transport protein Sec24A Human genes 0.000 description 3
- 102100040747 Protein zer-1 homolog Human genes 0.000 description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- 102100025165 Rab GTPase-activating protein 1-like, isoform 10 Human genes 0.000 description 3
- 102100025003 Ras-related protein R-Ras2 Human genes 0.000 description 3
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 description 3
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 3
- 101710110386 Rho GTPase-activating protein 12 Proteins 0.000 description 3
- 108050009586 Ribosomal protein L28 Proteins 0.000 description 3
- 101150097162 SERPING1 gene Proteins 0.000 description 3
- 101710161467 SH3 domain-binding protein 1 Proteins 0.000 description 3
- 108091006207 SLC-Transporter Proteins 0.000 description 3
- 102000037054 SLC-Transporter Human genes 0.000 description 3
- 108091007406 SLC64A1 Proteins 0.000 description 3
- 102100023521 SPATS2-like protein Human genes 0.000 description 3
- 101710168421 Signal-regulatory protein beta-1 Proteins 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 description 3
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 3
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 3
- 101710146918 Zinc finger protein 335 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013145 classification model Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 108010085650 interferon gamma receptor Proteins 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 108010076573 phosphoserine phosphatase Proteins 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000005333 pulmonary edema Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 108010092936 ribosomal protein S21 Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 102100030471 1-acyl-sn-glycerol-3-phosphate acyltransferase delta Human genes 0.000 description 2
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 description 2
- GXAFMKJFWWBYNW-OWHBQTKESA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC2CC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GXAFMKJFWWBYNW-OWHBQTKESA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 101710187872 60S ribosomal protein L36 Proteins 0.000 description 2
- 102100036605 AN1-type zinc finger protein 6 Human genes 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102100021641 Acetyl-CoA carboxylase 2 Human genes 0.000 description 2
- 102100030446 Adenosine 5'-monophosphoramidase HINT1 Human genes 0.000 description 2
- 102100021763 Alpha-mannosidase 2x Human genes 0.000 description 2
- 101710168921 Amyloid beta precursor like protein 2 Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 2
- 102100025351 C-type mannose receptor 2 Human genes 0.000 description 2
- 102100021703 C3a anaphylatoxin chemotactic receptor Human genes 0.000 description 2
- 102100031170 CCN family member 3 Human genes 0.000 description 2
- 102100024209 CD177 antigen Human genes 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- 102100029801 Calcium-transporting ATPase type 2C member 1 Human genes 0.000 description 2
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 2
- 102100023255 Centrosomal protein of 162 kDa Human genes 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102100035595 Cohesin subunit SA-2 Human genes 0.000 description 2
- 102100030977 Collagen alpha-3(IX) chain Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 108010009367 Cyclin-Dependent Kinase Inhibitor p18 Proteins 0.000 description 2
- 108010009361 Cyclin-Dependent Kinase Inhibitor p19 Proteins 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- 108010000080 Cytochrome P-450 CYP2A6 Proteins 0.000 description 2
- 102100039925 Cytochrome b-c1 complex subunit 10 Human genes 0.000 description 2
- 102100033466 DENN domain-containing protein 1A Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100040792 DNA primase small subunit Human genes 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 102100022264 Disks large homolog 4 Human genes 0.000 description 2
- 102100031606 Docking protein 4 Human genes 0.000 description 2
- 102100024680 Double homeobox protein 4-like protein 2 Human genes 0.000 description 2
- 102100024681 Double homeobox protein 4-like protein 4 Human genes 0.000 description 2
- 102100024675 Double homeobox protein 4-like protein 5 Human genes 0.000 description 2
- 102100024676 Double homeobox protein 4-like protein 7 Human genes 0.000 description 2
- 102100035863 E3 SUMO-protein ligase ZNF451 Human genes 0.000 description 2
- 102100031788 E3 ubiquitin-protein ligase MYLIP Human genes 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102100031863 Endoplasmic reticulum-Golgi intermediate compartment protein 2 Human genes 0.000 description 2
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 2
- 102100021381 Eukaryotic translation elongation factor 1 epsilon-1 Human genes 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 102100029378 Follistatin-related protein 1 Human genes 0.000 description 2
- 102100038643 Four and a half LIM domains protein 3 Human genes 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 108030000900 Glycine C-acetyltransferases Proteins 0.000 description 2
- 102100040517 Golgi-associated kinase 1B Human genes 0.000 description 2
- 102100030385 Granzyme B Human genes 0.000 description 2
- 102100028541 Guanylate-binding protein 2 Human genes 0.000 description 2
- 101710155787 HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 2
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 description 2
- 108010040960 HLA-DRB4 Chains Proteins 0.000 description 2
- 102000043280 Hemoglobin, zeta Human genes 0.000 description 2
- 102100033985 Heterogeneous nuclear ribonucleoprotein D0 Human genes 0.000 description 2
- 102100028177 High mobility group nucleosome-binding domain-containing protein 4 Human genes 0.000 description 2
- 101710192083 Histone H1.0 Proteins 0.000 description 2
- 102100029695 Homeobox protein Meis1 Human genes 0.000 description 2
- 102100028171 Homeobox-containing protein 1 Human genes 0.000 description 2
- 102100023603 Homer protein homolog 3 Human genes 0.000 description 2
- 101001126450 Homo sapiens 1-acyl-sn-glycerol-3-phosphate acyltransferase delta Proteins 0.000 description 2
- 101000782083 Homo sapiens AN1-type zinc finger protein 6 Proteins 0.000 description 2
- 101000677540 Homo sapiens Acetyl-CoA carboxylase 2 Proteins 0.000 description 2
- 101000615966 Homo sapiens Alpha-mannosidase 2x Proteins 0.000 description 2
- 101000916059 Homo sapiens C-X-C chemokine receptor type 2 Proteins 0.000 description 2
- 101000576898 Homo sapiens C-type mannose receptor 2 Proteins 0.000 description 2
- 101000896583 Homo sapiens C3a anaphylatoxin chemotactic receptor Proteins 0.000 description 2
- 101000777555 Homo sapiens CCN family member 3 Proteins 0.000 description 2
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000728145 Homo sapiens Calcium-transporting ATPase type 2C member 1 Proteins 0.000 description 2
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 2
- 101000908160 Homo sapiens Centrosomal protein of 162 kDa Proteins 0.000 description 2
- 101000919644 Homo sapiens Collagen alpha-3(IX) chain Proteins 0.000 description 2
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 2
- 101000607479 Homo sapiens Cytochrome b-c1 complex subunit 10 Proteins 0.000 description 2
- 101000870904 Homo sapiens DENN domain-containing protein 1A Proteins 0.000 description 2
- 101000611567 Homo sapiens DNA primase small subunit Proteins 0.000 description 2
- 101000902096 Homo sapiens Disks large homolog 4 Proteins 0.000 description 2
- 101000908465 Homo sapiens Double homeobox protein 4-like protein 2 Proteins 0.000 description 2
- 101000908466 Homo sapiens Double homeobox protein 4-like protein 4 Proteins 0.000 description 2
- 101000908450 Homo sapiens Double homeobox protein 4-like protein 5 Proteins 0.000 description 2
- 101000908452 Homo sapiens Double homeobox protein 4-like protein 7 Proteins 0.000 description 2
- 101000920800 Homo sapiens Endoplasmic reticulum-Golgi intermediate compartment protein 2 Proteins 0.000 description 2
- 101000938354 Homo sapiens Ephrin type-A receptor 1 Proteins 0.000 description 2
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 description 2
- 101001062535 Homo sapiens Follistatin-related protein 1 Proteins 0.000 description 2
- 101001031716 Homo sapiens Four and a half LIM domains protein 3 Proteins 0.000 description 2
- 101000893979 Homo sapiens Golgi-associated kinase 1B Proteins 0.000 description 2
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 2
- 101001058858 Homo sapiens Guanylate-binding protein 2 Proteins 0.000 description 2
- 101000843058 Homo sapiens Hemoglobin subunit zeta Proteins 0.000 description 2
- 101001006375 Homo sapiens High mobility group nucleosome-binding domain-containing protein 4 Proteins 0.000 description 2
- 101001006354 Homo sapiens Homeobox-containing protein 1 Proteins 0.000 description 2
- 101001048461 Homo sapiens Homer protein homolog 3 Proteins 0.000 description 2
- 101000614594 Homo sapiens Jerky protein homolog-like Proteins 0.000 description 2
- 101001006882 Homo sapiens Kelch-like protein 22 Proteins 0.000 description 2
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 2
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 description 2
- 101001091610 Homo sapiens Krev interaction trapped protein 1 Proteins 0.000 description 2
- 101001042354 Homo sapiens LIM and senescent cell antigen-like-containing domain protein 2 Proteins 0.000 description 2
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 description 2
- 101001055087 Homo sapiens MAP3K7 C-terminal-like protein Proteins 0.000 description 2
- 101000636206 Homo sapiens Matrix remodeling-associated protein 8 Proteins 0.000 description 2
- 101000963131 Homo sapiens Membralin Proteins 0.000 description 2
- 101000613610 Homo sapiens Monocyte to macrophage differentiation factor Proteins 0.000 description 2
- 101000589015 Homo sapiens Myomesin-2 Proteins 0.000 description 2
- 101000635840 Homo sapiens Myosin regulatory light chain 10 Proteins 0.000 description 2
- 101001111288 Homo sapiens NFU1 iron-sulfur cluster scaffold homolog, mitochondrial Proteins 0.000 description 2
- 101000634768 Homo sapiens Nucleolar protein 16 Proteins 0.000 description 2
- 101000613984 Homo sapiens Origin recognition complex subunit 2 Proteins 0.000 description 2
- 101000611312 Homo sapiens Pancreatic progenitor cell differentiation and proliferation factor Proteins 0.000 description 2
- 101001060744 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 description 2
- 101000929663 Homo sapiens Phospholipid-transporting ATPase ABCA7 Proteins 0.000 description 2
- 101000605827 Homo sapiens Pinin Proteins 0.000 description 2
- 101001124937 Homo sapiens Pre-mRNA-splicing factor 38B Proteins 0.000 description 2
- 101000617727 Homo sapiens Pregnancy-specific beta-1-glycoprotein 4 Proteins 0.000 description 2
- 101001048764 Homo sapiens Protein FAM118A Proteins 0.000 description 2
- 101000966243 Homo sapiens Protein LMBR1L Proteins 0.000 description 2
- 101000983130 Homo sapiens Protein kinase C and casein kinase substrate in neurons protein 2 Proteins 0.000 description 2
- 101000654448 Homo sapiens Protein transport protein Sec16A Proteins 0.000 description 2
- 101000616974 Homo sapiens Pumilio homolog 1 Proteins 0.000 description 2
- 101001136671 Homo sapiens Putative phosphoserine phosphatase-like protein Proteins 0.000 description 2
- 101001082184 Homo sapiens Pyrin and HIN domain-containing protein 1 Proteins 0.000 description 2
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 2
- 101000686903 Homo sapiens Reticulophagy regulator 1 Proteins 0.000 description 2
- 101000630197 Homo sapiens Rho GTPase-activating protein SYDE1 Proteins 0.000 description 2
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 description 2
- 101001093937 Homo sapiens SEC14-like protein 1 Proteins 0.000 description 2
- 101100203925 Homo sapiens SORBS1 gene Proteins 0.000 description 2
- 101000654734 Homo sapiens Septin-4 Proteins 0.000 description 2
- 101000616761 Homo sapiens Single-minded homolog 2 Proteins 0.000 description 2
- 101000863677 Homo sapiens Sodium/hydrogen exchanger 8 Proteins 0.000 description 2
- 101000633807 Homo sapiens TELO2-interacting protein 2 Proteins 0.000 description 2
- 101000796134 Homo sapiens Thymidine phosphorylase Proteins 0.000 description 2
- 101000642514 Homo sapiens Transcription factor SOX-4 Proteins 0.000 description 2
- 101000680652 Homo sapiens Tripartite motif-containing protein 14 Proteins 0.000 description 2
- 101000830570 Homo sapiens Tumor necrosis factor alpha-induced protein 3 Proteins 0.000 description 2
- 101000611185 Homo sapiens Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 2
- 101000941170 Homo sapiens U6 snRNA phosphodiesterase 1 Proteins 0.000 description 2
- 101000806601 Homo sapiens V-type proton ATPase catalytic subunit A Proteins 0.000 description 2
- 101000802101 Homo sapiens mRNA decay activator protein ZFP36L2 Proteins 0.000 description 2
- 241000342334 Human metapneumovirus Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010058179 Hypertensive emergency Diseases 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 2
- 101710148793 Intercellular adhesion molecule 4 Proteins 0.000 description 2
- 102100040506 Jerky protein homolog-like Human genes 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 102100027793 Kelch-like protein 22 Human genes 0.000 description 2
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 2
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 102100021755 LIM and senescent cell antigen-like-containing domain protein 2 Human genes 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 102100021958 Lysyl oxidase homolog 1 Human genes 0.000 description 2
- 102100026906 MAP3K7 C-terminal-like protein Human genes 0.000 description 2
- 102100030777 Matrix remodeling-associated protein 8 Human genes 0.000 description 2
- 238000001347 McNemar's test Methods 0.000 description 2
- 102100039605 Membralin Human genes 0.000 description 2
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- 102100040849 Monocyte to macrophage differentiation factor Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 102100032965 Myomesin-2 Human genes 0.000 description 2
- 102100030857 Myosin regulatory light chain 10 Human genes 0.000 description 2
- 102100024011 NFU1 iron-sulfur cluster scaffold homolog, mitochondrial Human genes 0.000 description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 2
- 102000048238 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 102100026379 Neurofibromin Human genes 0.000 description 2
- 108010085793 Neurofibromin 1 Proteins 0.000 description 2
- 101710117081 Neutrophil defensin 1 Proteins 0.000 description 2
- 208000031662 Noncommunicable disease Diseases 0.000 description 2
- 102100029102 Nucleolar protein 16 Human genes 0.000 description 2
- 102100040608 Origin recognition complex subunit 2 Human genes 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 102100036878 PHD finger protein 20 Human genes 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102100040332 Pancreatic progenitor cell differentiation and proliferation factor Human genes 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
- 102100027506 Peroxisomal trans-2-enoyl-CoA reductase Human genes 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 102100036620 Phospholipid-transporting ATPase ABCA7 Human genes 0.000 description 2
- 102100038374 Pinin Human genes 0.000 description 2
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 2
- 102100040748 Polyglutamine-binding protein 1 Human genes 0.000 description 2
- 102100029436 Pre-mRNA-splicing factor 38B Human genes 0.000 description 2
- 102100022021 Pregnancy-specific beta-1-glycoprotein 4 Human genes 0.000 description 2
- 102100021567 Protein BANP Human genes 0.000 description 2
- 102100023783 Protein FAM118A Human genes 0.000 description 2
- 102100040549 Protein LMBR1L Human genes 0.000 description 2
- 102100026843 Protein kinase C and casein kinase substrate in neurons protein 2 Human genes 0.000 description 2
- 102100031479 Protein transport protein Sec16A Human genes 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102100021672 Pumilio homolog 1 Human genes 0.000 description 2
- 102100036656 Putative phosphoserine phosphatase-like protein Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 2
- 102100027365 Pyrin and HIN domain-containing protein 1 Human genes 0.000 description 2
- 101710152724 Pyruvate kinase PKM Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102100027512 RNA-binding protein 12 Human genes 0.000 description 2
- 101710203308 RNA-binding protein 12 Proteins 0.000 description 2
- 101710154822 Ras-related protein R-Ras2 Proteins 0.000 description 2
- 102100024734 Reticulophagy regulator 1 Human genes 0.000 description 2
- 102100026203 Rho GTPase-activating protein SYDE1 Human genes 0.000 description 2
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 2
- 102100035214 SEC14-like protein 1 Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100021825 Single-minded homolog 2 Human genes 0.000 description 2
- 102100023102 Solute carrier family 22 member 18 Human genes 0.000 description 2
- 102100026834 Sorbin and SH3 domain-containing protein 1 Human genes 0.000 description 2
- 102100030056 Splicing factor 1 Human genes 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
- 102100029259 TELO2-interacting protein 2 Human genes 0.000 description 2
- 102100033128 Transcription factor 15 Human genes 0.000 description 2
- 102100036693 Transcription factor SOX-4 Human genes 0.000 description 2
- 102100032472 Transmembrane protease serine 5 Human genes 0.000 description 2
- 101710081839 Transmembrane protease serine 6 Proteins 0.000 description 2
- 102100027030 Transmembrane protein 140 Human genes 0.000 description 2
- 102100029732 Transmembrane protein 180 Human genes 0.000 description 2
- 102100022350 Tripartite motif-containing protein 14 Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100029298 Tubby-related protein 3 Human genes 0.000 description 2
- 102100021163 Tubulinyl-Tyr carboxypeptidase 1 Human genes 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 102100024578 Tyrosyl-DNA phosphodiesterase 2 Human genes 0.000 description 2
- 102100031314 U6 snRNA phosphodiesterase 1 Human genes 0.000 description 2
- 102100037466 V-type proton ATPase catalytic subunit A Human genes 0.000 description 2
- 102100028885 Vitamin K-dependent protein S Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 238000011203 antimicrobial therapy Methods 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000005182 global health Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000010468 interferon response Effects 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 108010079923 lambda Spi-1 Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108010089086 lysolecithin acylhydrolase Proteins 0.000 description 2
- 102100034703 mRNA decay activator protein ZFP36L2 Human genes 0.000 description 2
- 201000005857 malignant hypertension Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000007837 multiplex assay Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000006855 networking Effects 0.000 description 2
- 230000008518 non respiratory effect Effects 0.000 description 2
- 230000012223 nuclear import Effects 0.000 description 2
- 230000025308 nuclear transport Effects 0.000 description 2
- 102000037831 nucleoside transporters Human genes 0.000 description 2
- 108091006527 nucleoside transporters Proteins 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 108010068698 spleen exonuclease Proteins 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- PERRGDHWJANTGV-ZLELNMGESA-N (2s)-6-amino-2-(phosphonoamino)hexanoic acid;(2s)-3-(1h-imidazol-5-yl)-2-(phosphonoamino)propanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NP(O)(O)=O.OP(=O)(O)N[C@H](C(=O)O)CC1=CNC=N1 PERRGDHWJANTGV-ZLELNMGESA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- SAUCHDKDCUROAO-UHFFFAOYSA-N 2-amino-3-oxobutanoic acid Chemical compound CC(=O)C(N)C(O)=O SAUCHDKDCUROAO-UHFFFAOYSA-N 0.000 description 1
- 102100032411 60S ribosomal protein L18 Human genes 0.000 description 1
- 102100033926 AP-3 complex subunit delta-1 Human genes 0.000 description 1
- 101150006923 ARI gene Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 101710126783 Acetyl-hydrolase Proteins 0.000 description 1
- 241001673062 Achromobacter xylosoxidans Species 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 101710183653 Actin-related protein 2/3 complex subunit 3 Proteins 0.000 description 1
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 1
- 102000007476 Activating Transcription Factor 3 Human genes 0.000 description 1
- 108010085371 Activating Transcription Factor 3 Proteins 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108010077835 Adaptor Protein Complex 3 Proteins 0.000 description 1
- 102000010646 Adaptor Protein Complex 3 Human genes 0.000 description 1
- 101710163062 Adenosine 5'-monophosphoramidase HINT1 Proteins 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108090000084 Antiporters Proteins 0.000 description 1
- 102000003669 Antiporters Human genes 0.000 description 1
- 101100378610 Arabidopsis thaliana AGL3 gene Proteins 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108010001572 Basic-Leucine Zipper Transcription Factors Proteins 0.000 description 1
- 102000000806 Basic-Leucine Zipper Transcription Factors Human genes 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000124740 Bocaparvovirus Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101710113502 Branchpoint-bridging protein Proteins 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 101710150565 CDK5 regulatory subunit-associated protein 2 Proteins 0.000 description 1
- 108010040163 CREB-Binding Protein Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000906729 Capsodes Species 0.000 description 1
- 101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 208000017781 Cocaine intoxication Diseases 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 101710173933 Cohesin subunit SA-2 Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 description 1
- 102100035436 Complement factor D Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 102100034976 Cystathionine beta-synthase Human genes 0.000 description 1
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 1
- 101710101760 Cytochrome P450 2A7 Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010060682 DEAD Box Protein 58 Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 101150034979 DRB3 gene Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101710131749 Docking protein 4 Proteins 0.000 description 1
- 102100024679 Double homeobox protein 4-like protein 3 Human genes 0.000 description 1
- 102100024678 Double homeobox protein 4-like protein 6 Human genes 0.000 description 1
- 102100021159 Double homeobox protein 4C Human genes 0.000 description 1
- 101100114828 Drosophila melanogaster Orai gene Proteins 0.000 description 1
- 101710184191 E3 SUMO-protein ligase ZNF451 Proteins 0.000 description 1
- 101710190174 E3 ubiquitin-protein ligase MYLIP Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000217440 Echovirus E3 Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101710166419 Eukaryotic translation elongation factor 1 epsilon-1 Proteins 0.000 description 1
- 102100029602 Eukaryotic translation initiation factor 4B Human genes 0.000 description 1
- 101710092092 Eukaryotic translation initiation factor 4B Proteins 0.000 description 1
- 102100026765 Eukaryotic translation initiation factor 4H Human genes 0.000 description 1
- 101710091914 Eukaryotic translation initiation factor 4H Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101710120490 Exosome complex component Rrp41 Proteins 0.000 description 1
- 208000009087 False Aneurysm Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710130475 Formin-binding protein 4 Proteins 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 1
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102100021514 HLA class I histocompatibility antigen protein P5 Human genes 0.000 description 1
- 101710188464 HLA class I histocompatibility antigen protein P5 Proteins 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 241000606841 Haemophilus sp. Species 0.000 description 1
- 206010019027 Haemothorax Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 108010085241 Heterogeneous-Nuclear Ribonucleoprotein D Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102100026119 High affinity immunoglobulin gamma Fc receptor IB Human genes 0.000 description 1
- 101710206030 High affinity immunoglobulin gamma Fc receptor IB Proteins 0.000 description 1
- 101710094174 Histidine triad nucleotide-binding protein 1 Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 101001077332 Homo sapiens 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Proteins 0.000 description 1
- 101001087985 Homo sapiens 60S ribosomal protein L18 Proteins 0.000 description 1
- 101001110263 Homo sapiens 60S ribosomal protein L36 Proteins 0.000 description 1
- 101000779252 Homo sapiens AP-3 complex subunit delta-1 Proteins 0.000 description 1
- 101000842270 Homo sapiens Adenosine 5'-monophosphoramidase HINT1 Proteins 0.000 description 1
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 description 1
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 1
- 101000642968 Homo sapiens Cohesin subunit SA-2 Proteins 0.000 description 1
- 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 description 1
- 101000737554 Homo sapiens Complement factor D Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000845690 Homo sapiens Docking protein 4 Proteins 0.000 description 1
- 101000908467 Homo sapiens Double homeobox protein 4-like protein 3 Proteins 0.000 description 1
- 101000908449 Homo sapiens Double homeobox protein 4-like protein 6 Proteins 0.000 description 1
- 101000968551 Homo sapiens Double homeobox protein 4C Proteins 0.000 description 1
- 101000782473 Homo sapiens E3 SUMO-protein ligase ZNF451 Proteins 0.000 description 1
- 101001128447 Homo sapiens E3 ubiquitin-protein ligase MYLIP Proteins 0.000 description 1
- 101000615221 Homo sapiens Eukaryotic translation elongation factor 1 epsilon-1 Proteins 0.000 description 1
- 101001051087 Homo sapiens Galectin-10 Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101001017535 Homo sapiens Heterogeneous nuclear ribonucleoprotein D0 Proteins 0.000 description 1
- 101001013393 Homo sapiens Homeobox protein Meis1 Proteins 0.000 description 1
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 description 1
- 101000961145 Homo sapiens Immunoglobulin heavy constant gamma 3 Proteins 0.000 description 1
- 101001037138 Homo sapiens Immunoglobulin heavy variable 3-11 Proteins 0.000 description 1
- 101001053339 Homo sapiens Inositol polyphosphate 4-phosphatase type II Proteins 0.000 description 1
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 1
- 101001047515 Homo sapiens Lethal(2) giant larvae protein homolog 1 Proteins 0.000 description 1
- 101001033726 Homo sapiens Methyl-CpG-binding protein 2 Proteins 0.000 description 1
- 101000655246 Homo sapiens Neutral amino acid transporter A Proteins 0.000 description 1
- 101001071230 Homo sapiens PHD finger protein 20 Proteins 0.000 description 1
- 101000579913 Homo sapiens Peroxisomal trans-2-enoyl-CoA reductase Proteins 0.000 description 1
- 101000981515 Homo sapiens Phospholysine phosphohistidine inorganic pyrophosphate phosphatase Proteins 0.000 description 1
- 101000583156 Homo sapiens Pituitary homeobox 1 Proteins 0.000 description 1
- 101001097889 Homo sapiens Platelet-activating factor acetylhydrolase Proteins 0.000 description 1
- 101000611427 Homo sapiens Polyglutamine-binding protein 1 Proteins 0.000 description 1
- 101000971151 Homo sapiens Protein BANP Proteins 0.000 description 1
- 101001033660 Homo sapiens Protein IMPACT Proteins 0.000 description 1
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 1
- 101000658082 Homo sapiens Putative U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 1 Proteins 0.000 description 1
- 101000579758 Homo sapiens Raftlin Proteins 0.000 description 1
- 101000686227 Homo sapiens Ras-related protein R-Ras2 Proteins 0.000 description 1
- 101000584785 Homo sapiens Ras-related protein Rab-7a Proteins 0.000 description 1
- 101000685678 Homo sapiens Solute carrier family 22 member 18 Proteins 0.000 description 1
- 101001056878 Homo sapiens Squalene monooxygenase Proteins 0.000 description 1
- 101000934888 Homo sapiens Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Proteins 0.000 description 1
- 101000826399 Homo sapiens Sulfotransferase 1A1 Proteins 0.000 description 1
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 description 1
- 101000800563 Homo sapiens Transcription factor 15 Proteins 0.000 description 1
- 101000798704 Homo sapiens Transmembrane protease serine 5 Proteins 0.000 description 1
- 101000763474 Homo sapiens Transmembrane protein 140 Proteins 0.000 description 1
- 101001012550 Homo sapiens Transmembrane protein 180 Proteins 0.000 description 1
- 101000772167 Homo sapiens Tubby-related protein 3 Proteins 0.000 description 1
- 101000750285 Homo sapiens Tubulinyl-Tyr carboxypeptidase 1 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101000760781 Homo sapiens Tyrosyl-DNA phosphodiesterase 2 Proteins 0.000 description 1
- 101000577630 Homo sapiens Vitamin K-dependent protein S Proteins 0.000 description 1
- 101000723815 Homo sapiens Zinc finger CCHC domain-containing protein 14 Proteins 0.000 description 1
- 101000856554 Homo sapiens Zinc finger protein Gfi-1b Proteins 0.000 description 1
- 101000634977 Homo sapiens Zinc finger protein RFP Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 208000005420 Hyperemesis Gravidarum Diseases 0.000 description 1
- 206010020802 Hypertensive crisis Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 description 1
- 102100039348 Immunoglobulin heavy constant gamma 3 Human genes 0.000 description 1
- 102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 1
- 101710187617 Immunoglobulin heavy constant mu Proteins 0.000 description 1
- 102100040222 Immunoglobulin heavy variable 3-11 Human genes 0.000 description 1
- 102100040231 Immunoglobulin heavy variable 3-7 Human genes 0.000 description 1
- 101710098827 Immunoglobulin heavy variable 3-7 Proteins 0.000 description 1
- 102100028310 Immunoglobulin heavy variable 4-31 Human genes 0.000 description 1
- 101710196329 Immunoglobulin heavy variable 4-31 Proteins 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 102100024366 Inositol polyphosphate 4-phosphatase type II Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 101710174027 Interferon gamma receptor 2 Proteins 0.000 description 1
- 101710197212 Interferon-induced protein 44 Proteins 0.000 description 1
- 101710142533 Interferon-induced protein 44-like Proteins 0.000 description 1
- 101710166698 Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 description 1
- 101710166376 Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 description 1
- 101710087399 Interferon-induced transmembrane protein 1 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589268 Legionella sp. Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 108010009489 Lysosomal-Associated Membrane Protein 3 Proteins 0.000 description 1
- 101150083522 MECP2 gene Proteins 0.000 description 1
- 101150029107 MEIS1 gene Proteins 0.000 description 1
- 101710088724 MTOR-associated protein MEAK7 Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000896532 Mus musculus C3a anaphylatoxin chemotactic receptor Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108700041619 Myeloid Ecotropic Viral Integration Site 1 Proteins 0.000 description 1
- 102000012064 NLR Proteins Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010049358 Oncogene Protein p65(gag-jun) Proteins 0.000 description 1
- 108010062618 Oncogene Proteins v-rel Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010067472 Organising pneumonia Diseases 0.000 description 1
- 101000913038 Ornithorhynchus anatinus Defensin-A1 Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 108091012461 PHD finger protein 20 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000025443 POZ domain binding proteins Human genes 0.000 description 1
- 108091014659 POZ domain binding proteins Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000983368 Pantoea sp. Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KJWMGLBVDNMNQW-VWTMXFPPSA-N Pectenotoxin 1 Chemical compound O[C@@H]1[C@H](C)CCO[C@]1(O)[C@H]1O[C@@H]2/C=C/C(/C)=C/[C@H](C)C[C@](C)(O3)CC[C@@H]3[C@](O3)(O4)CC[C@@]3(CO)C[C@@H]4[C@@H](O3)C(=O)C[C@]3(C)[C@@H](O)[C@@H](O3)CC[C@@]3(O3)CCC[C@H]3[C@@H](C)C(=O)O[C@@H]2C1 KJWMGLBVDNMNQW-VWTMXFPPSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 229940122344 Peptidase inhibitor Drugs 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710134558 Peroxisomal trans-2-enoyl-CoA reductase Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 102100024111 Phospholysine phosphohistidine inorganic pyrophosphate phosphatase Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100037518 Platelet-activating factor acetylhydrolase Human genes 0.000 description 1
- 206010035734 Pneumonia staphylococcal Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710149001 Protein BANP Proteins 0.000 description 1
- 102100039097 Protein IMPACT Human genes 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 102100033192 Puromycin-sensitive aminopeptidase Human genes 0.000 description 1
- 102100035035 Putative U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 1 Human genes 0.000 description 1
- 102100039233 Pyrin Human genes 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 101710133282 RNA-binding protein 1 Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102100028208 Raftlin Human genes 0.000 description 1
- 102100030019 Ras-related protein Rab-7a Human genes 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 102000003926 Ribosomal protein L18 Human genes 0.000 description 1
- 108090000343 Ribosomal protein L18 Proteins 0.000 description 1
- 208000004717 Ruptured Aneurysm Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 102000041863 SEC24 family Human genes 0.000 description 1
- 108091079690 SEC24 family Proteins 0.000 description 1
- 102000012978 SLC1A4 Human genes 0.000 description 1
- 108091006750 SLC22A18 Proteins 0.000 description 1
- 108091006647 SLC9A1 Proteins 0.000 description 1
- 101710127283 Septin-4 Proteins 0.000 description 1
- 101150117471 Septin4 gene Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010041101 Small intestinal obstruction Diseases 0.000 description 1
- 101710201924 Sphingomyelin phosphodiesterase 1 Proteins 0.000 description 1
- 101710095280 Sphingomyelinase C 1 Proteins 0.000 description 1
- 101710153291 Splicing factor 1 Proteins 0.000 description 1
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 1
- 108020003891 Squalene monooxygenase Proteins 0.000 description 1
- 102100025560 Squalene monooxygenase Human genes 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 102100025393 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100023986 Sulfotransferase 1A1 Human genes 0.000 description 1
- 102000004896 Sulfotransferases Human genes 0.000 description 1
- 108090001033 Sulfotransferases Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 102100038618 Thymidylate synthase Human genes 0.000 description 1
- 208000004607 Tracheobronchomalacia Diseases 0.000 description 1
- 101710119705 Transcription factor 15 Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 101710081833 Transmembrane protease serine 5 Proteins 0.000 description 1
- 101710170870 Transmembrane protein 140 Proteins 0.000 description 1
- 101710191744 Transmembrane protein 180 Proteins 0.000 description 1
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 1
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 1
- 101710147740 Tubby-related protein 3 Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108050001467 Tubulinyl-Tyr carboxypeptidase 1 Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 108010080432 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Proteins 0.000 description 1
- 102100034461 U2 small nuclear ribonucleoprotein B'' Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010048975 Vascular pseudoaneurysm Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 101710193896 Vitamin K-dependent protein S Proteins 0.000 description 1
- 208000005248 Vocal Cord Paralysis Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 101710199425 XIAP-associated factor 1 Proteins 0.000 description 1
- 102100028477 Zinc finger CCHC domain-containing protein 14 Human genes 0.000 description 1
- 102100025531 Zinc finger protein Gfi-1b Human genes 0.000 description 1
- 102100029504 Zinc finger protein RFP Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 102000009899 alpha Karyopherins Human genes 0.000 description 1
- 108010077099 alpha Karyopherins Proteins 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 230000007487 asymptomatic viral shedding Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000007940 bacterial gene expression Effects 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000723 chemosensory effect Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 108700041286 delta Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000036124 hormone binding proteins Human genes 0.000 description 1
- 108091011044 hormone binding proteins Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940124625 intravenous corticosteroids Drugs 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940125389 long-acting beta agonist Drugs 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108010043629 phosphatidylinositol-3,4-bisphosphate 4-phosphatase Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 108010030799 polyglutamine-binding protein 1 Proteins 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 229940125390 short-acting beta agonist Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 108010039827 snRNP Core Proteins Proteins 0.000 description 1
- 102000015380 snRNP Core Proteins Human genes 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000004048 staphylococcal pneumonia Diseases 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 208000011437 staphylococcus aureus pneumonia Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 108091023025 thyroid hormone binding Proteins 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 230000000982 vasogenic effect Effects 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 208000020017 viral respiratory tract infection Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 101150034188 zyg11 gene Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Definitions
- Acute respiratory infection is common in acute care environments and results in significant mortality, morbidity, and economic losses worldwide.
- Respiratory tract infections, or acute respiratory infections (ARI) caused 3.2 million deaths around the world and 164 million disability-adjusted life years lost in 2011, more than any other cause (World Health Organization., 2013a, 2013b).
- ARI acute respiratory infections
- the fourth leading cause of death worldwide was lower respiratory tract infections, and in low and middle income countries, where less supportive care is available, lower respiratory tract infections are the leading cause of death (WHO factsheet, accessed August 22, 2014).
- WHO factsheet accessed August 22, 2014.
- These illnesses are also problematic in developed countries.
- the Centers for Disease Control (CDC) determined that pneumonia and influenza alone caused 15.1 deaths for every 100,000 people in the US population.
- the aged and children under the age of 5 years are particularly vulnerable to poor outcomes due to ARIs.
- pneumonia accounted for 18.3% of all deaths, or almost 1.4 million deaths, worldwide in children aged 5 years or younger.
- Pneumonia and other lower respiratory tract infections can be due to many different pathogens that are primarily viral, bacterial, or less frequently fungal.
- influenza is among the most notorious based on numbers of affected individuals, variable severity from season to season, and the ever-present worry about new strains causing much higher morbidity and mortality (e.g., Avian flu).
- Avian flu e.g., Avian flu
- influenza is only one of many that cause significant human disease.
- Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization of children in developed countries during the winter months. Worldwide, about 33 million new cases of RSV infections were reported in 2005 in children under 5, with 3.4 million severe enough for hospitalization. It is estimated that this viral infection alone kills between 66,000 and 199,000 children each year.
- bacterial etiologies are also prominent especially in the context of lower respiratory tract infections.
- Specific causes of bacterial ARI vary geographically and by clinical context but include Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae, Klebsiella pneumoniae, Escherichia coli , and Pseudomonas aeruginosa .
- Streptococcus pneumoniae Staphylococcus aureus
- Haemophilus influenzae Chlamydia pneumoniae
- Mycoplasma pneumoniae Mycoplasma pneumoniae
- Klebsiella pneumoniae Klebsiella pneumoniae
- Escherichia coli Escherichia coli
- Pseudomonas aeruginosa The identification of these pathogens relies on their growth in culture, which typically requires days and has limited sensitivity for detection of the infectious agent.
- Acute respiratory infections are frequently characterized by non-specific symptoms (such as fever or cough) that are common to many different illnesses, including illnesses that are not caused by an infection.
- Existing diagnostics for ARI fall short in a number of ways.
- Conventional microbiological testing is limited by poor sensitivity and specificity, slow turn-around times, or by the complexity of the test (Zaas et al. 2014, Trends Mol Med 20(10):579-88).
- One limitation of current tests that detect specific viral pathogens for example the multiplex PCR-based assays, is the inability to detect emergent or pandemic viral strains. Influenza pandemics arise when new viruses circulate against which populations have no natural resistance. Influenza pandemics are frequently devastating.
- the Spanish flu affected about 20% to 40% of the world's population and killed about 50 million people; in 1957-1958, Asian flu killed about 2 million people; in 1968-1969 the Hong Kong flu killed about 1 million people; and in 2009-2010, the Centers for Disease Control estimates that approximately 43 million to 89 million people contracted swine flu resulting in 8,870 to 18,300 related deaths.
- the emergence of these new strains challenges existing diagnostics which are not designed to detect them. This was particularly evident during the 2009 influenza pandemic where confirmation of infection required days and only occurred at specialized testing centers such as state health departments or the CDC (Kumar & Henrickson 2012, Clin Microbiol Rev 25(2):344-61).
- the Ebola virus disease outbreak in West Africa poses similar challenges at the present time. Moreover, there is every expectation we will continue to face this issue as future outbreaks of infectious diseases are inevitable.
- a further limitation of diagnostics that use the paradigm of testing for specific viruses or bacteria is that even though a pathogenic microbe may be detected, this is not proof that the patient's symptoms are due to the detected pathogen.
- a microorganism may be present as part of the individual's normal flora, known as colonization, or it may be detected due to contamination of the tested sample (e.g., a nasal swab or wash).
- recently-approved multiplex PCR assays including those that detect viruses and bacteria, offer high sensitivity, these tests do not differentiate between asymptomatic carriage of a virus and true infection. For example, there is a high rate of asymptomatic viral shedding in ARI, particularly in children (Jansen et al. 2011, J Clin Microbiol 49(7):2631-2636). Similarly, even though one pathogen is detected, illness may be due to a second pathogen for which there was no test available or performed.
- the present disclosure provides, in part, a molecular diagnostic test that overcomes many of the limitations of current methods for the determination of the etiology of respiratory symptoms.
- the test detects the host's response to an infectious agent or agents by measuring and analyzing the patterns of co-expressed genes, or signatures. These gene expression signatures may be measured in a blood sample in a human or animal presenting with symptoms that are consistent with an acute respiratory infection or in a human or animal that is at risk of developing (e.g., presymptomatic) an acute respiratory infection (e.g., during an epidemic or local disease outbreak).
- Measurement of the host response as taught herein differentiates between bacterial ARI, viral ARI, and a non-infectious cause of illness, and may also detect ARI resulting from co-infection with bacteria and virus.
- This multi-component test performs with unprecedented accuracy and clinical applicability, allowing health care providers to use the response of the host (the subject or patient) to reliably determine the nature of the infectious agent, to the level of pathogen class, or to exclude an infectious cause of symptoms in an individual patient presenting with symptoms that, by themselves, are not specific.
- the results are agnostic to the species of respiratory virus or bacteria (i.e., while differentiating between virus or bacteria, it does not differentiate between particular genus or species of virus or bacteria). This offers an advantage over current tests that include probes or reagents directed to specific pathogens and thus are limited to detecting only those specific pathogens.
- One aspect of the present disclosure provides a method for determining whether acute respiratory symptoms in a subject are bacterial in origin, viral in origin, or non-infectious in origin comprising, consisting of, or consisting essentially of: (a) obtaining a biological sample from the subject; (b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes, termed signatures; (c) normalizing gene expression levels for the technology (i.e., platform) used to make said measurement to generate a normalized value; (d) entering the normalized values into a bacterial classifier, a viral classifier and/or a non-infectious illness classifier that have pre-defined weighting values (coefficients) for each of the genes in each signature; (e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; and (f) using the output to determine whether the patient providing the sample has an infection of bacterial origin, viral origin, or has a
- Another aspect of the present disclosure provides a method for determining whether an acute respiratory infection (ARI) in a subject is bacterial in origin, viral in origin, or non-infectious in origin comprising, consisting of, or consisting essentially of: (a) obtaining a biological sample from the subject; (b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes; (c) normalizing gene expression levels for the technology (i.e., platform) used to make said measurement to generate a normalized value; (d) entering the normalized value into classifiers that have pre-defined weighting values for each of the genes in each signature; e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; (f) if the sample is negative for bacteria, repeating step (d) using only the viral classifier and non-infectious classifier; and (g) classifying the sample as being of viral etiology or noninfectious illness.
- Another aspect of the present disclosure provides a method for determining whether an acute respiratory infection (ARI) in a subject is bacterial in origin, viral in origin, or non-infectious in origin comprising, consisting of, or consisting essentially of: (a) obtaining a biological sample from the subject; (b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes; (c) normalizing gene expression levels for the technology (i.e., platform) used to make said measurement to generate a normalized value; (d) entering the normalized values into classifiers that have pre-defined weighting values for each of the genes in each signature; (e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; (f) if the sample is negative for virus, repeating step (d) using only the bacteria classifier and non-infectious classifier; and (g) classifying the sample as being of bacterial etiology or noninfectious illness.
- Another aspect of the present disclosure provides a method for determining whether an acute respiratory infection (ARI) in a subject is bacterial in origin, viral in origin, or non-infectious in origin comprising, consisting of, or consisting essentially of: (a) obtaining a biological sample from the subject; (b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes; (c) normalizing gene expression levels for the technology (i.e., platform) used to make said measurement to generate a normalized value; (d) entering the normalized values into classifiers that have pre-defined weighting values for each of the genes in each signature; (e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; (f) if the sample is negative for non-infectious illness, repeating step (d) using only the viral classifier and bacterial classifier; and (g) classifying the sample as being of viral etiology or bacterial et
- Yet another aspect of the present disclosure provides a method of treating an acute respiratory infection (ARI) whose etiology is unknown in a subject, said method comprising, consisting of, or consisting essentially of: (a) obtaining a biological sample from the subject; (b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes (e.g., one, two or three or more signatures); (c) normalizing gene expression levels for the technology (i.e., platform) used to make said measurement to generate a normalized value; (d) entering the normalized values into a bacterial classifier, a viral classifier and non-infectious illness classifier that have pre-defined weighting values for each of the genes in each signature; (e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; (f) classifying the sample as being of bacterial etiology, viral etiology, or noninfectious illness;
- step (g) comprises administering an antibacterial therapy when the etiology of the ARI is determined to be bacterial. In other embodiments, step (g) comprises administering an antiviral therapy when the etiology of the ARI is determined to be viral.
- Another aspect is a method of monitoring response to a vaccine or a drug in a subject suffering from or at risk of an acute respiratory illness selected from bacterial, viral and/or non-infectious, comprising determining a host response of said subject, said determining carried out by a method as taught herein.
- the drug is an antibacterial drug or an antiviral drug.
- the methods further comprise generating a report assigning the subject a score indicating the probability of the etiology of the ARI.
- a system for determining an etiology of an acute respiratory illness in a subject selected from bacterial, viral and/or non-infectious comprising one or more of (inclusive of combinations thereof): at least one processor; a sample input circuit configured to receive a biological sample from the subject; a sample analysis circuit coupled to the at least one processor and configured to determine gene expression levels of the biological sample; an input/output circuit coupled to the at least one processor; a storage circuit coupled to the at least one processor and configured to store data, parameters, and/or classifiers; and a memory coupled to the processor and comprising computer readable program code embodied in the memory that when executed by the at least one processor causes the at least one processor to perform operations comprising: controlling/performing measurement via the sample analysis circuit of gene expression levels of a pre-defined set of genes (i.e., signature) in said biological sample; normalizing the gene expression levels to generate normalized gene expression values; retrieving from the storage circuit a bacterial acute respiratory infection (ARI) classifier, a viral ARI class
- the system comprises computer readable code to transform quantitative, or semi-quantitative, detection of gene expression to a cumulative score or probability of the etiology of the ARI.
- the system comprises an array platform, a thermal cycler platform (e.g., multiplexed and/or real-time PCR platform), a hybridization and multi-signal coded (e.g., fluorescence) detector platform, a nucleic acid mass spectrometry platform, a nucleic acid sequencing platform, or a combination thereof.
- a thermal cycler platform e.g., multiplexed and/or real-time PCR platform
- a hybridization and multi-signal coded (e.g., fluorescence) detector platform e.g., fluorescence detector platform
- a nucleic acid mass spectrometry platform e.g., a nucleic acid sequencing platform, or a combination thereof.
- the pre-defined sets of genes comprise at least three genetic signatures.
- the biological sample comprises a sample selected from the group consisting of peripheral blood, sputum, nasopharyngeal swab, nasopharyngeal wash, bronchoalveolar lavage, endotracheal aspirate, and combinations thereof.
- the bacterial classifier comprises expression levels of 5, 10, 20, 30 or 50, to 80, 100, 150 or 200 of the genes (measurable, e.g., with oligonucleotide probes homologous to said genes or gene transcripts) listed as part of a bacterial classifier in Table 1, Table 2, Table 9, Table 10 and/or Table 12.
- the viral classifier comprises expression levels of 5, 10, 20, 30 or 50, to 80, 100, 150 or 200 of the genes (measurable, e.g., with oligonucleotide probes homologous to said genes or gene transcripts) listed as part of a viral classifier in Table 1, Table 2, Table 9, Table 10 and/or Table 12.
- the non-infectious illness classifier comprises expression levels of 5, 10, 20, 30 or 50, to 80, 100, 150 or 200 of the genes (measurable, e.g., with oligonucleotide probes homologous to said genes or gene transcripts) listed as part of a non-infectious illness classifier in Table 1, Table 2, Table 9, Table 10 and/or Table 12.
- a kit for determining the etiology of an acute respiratory infection (ARI) in a subject comprising, consisting of, or consisting essentially of (a) a means for extracting mRNA from a biological sample; (b) a means for generating one or more arrays consisting of a plurality of synthetic oligonucleotides with regions homologous to transcripts from of 5, 10, 20, 30 or 50, to 80, 100, 150 or 200 of the genes from Table 1, Table 2, Table 9, Table 10 and/or Table 12; and (c) instructions for use.
- a means for extracting mRNA from a biological sample comprising, consisting of, or consisting essentially of (a) a means for extracting mRNA from a biological sample; (b) a means for generating one or more arrays consisting of a plurality of synthetic oligonucleotides with regions homologous to transcripts from of 5, 10, 20, 30 or 50, to 80, 100, 150 or 200 of the genes from Table 1, Table 2, Table 9, Table 10 and/or
- kits for assessing the acute respiratory infection (ARI) classifier comprising, consisting of, or consisting essentially of: (a) generating one or more arrays consisting of a plurality of synthetic oligonucleotides with regions homologous to of 5, 10, 20, 30 or 50, to 80, 100, 150 or 200 of the genes from Table 1, Table 2, Table 9, Table 10 and/or Table 12; (b) adding to said array oligonucleotides with regions homologous to normalizing genes; (c) obtaining a biological sample from a subject suffering from an acute respiratory infection (ARI); (d) isolating RNA from said sample to create a transcriptome; (e) measuring said transcriptome on said array (e.g., by measuring fluorescence or electric current proportional to the level of gene expression, etc.); (f) normalizing the measurements of said transcriptome to the normalizing genes, electronically transferring normalized measurements to a computer to implement the classifier(s), (g) generating a report; and
- the method further comprises externally validating an ARI classifier against a known dataset comprising at least two relevant clinical attributes.
- the dataset is selected from the group consisting of GSE6269, GSE42026, GSE40396, GSE20346, GSE42834 and combinations thereof.
- Yet another aspect of the present disclosure provides all that is disclosed and illustrated herein.
- ARI classifier as taught herein in a method of treatment for acute respiratory infection (ARI) in a subject of unknown etiology.
- FIG. 1 is a schematic showing a method of obtaining classifiers (training 10 ) according to some embodiments of the present disclosure, where each classifier is composed of a weighted sum of all or a subset of normalized gene expression levels. This weighted sum defines a probability that allows for a decision (classification), particularly when compared to a threshold value or a confidence interval.
- the exact combination of genes, their weights and the threshold for each classifier obtained by the training are particular to a specific platform.
- the classifier (or more precisely its components, namely weights and threshold or confidence interval (values)) go to a database. Weights with a nonzero value determine the subset of genes used by the classifier. Repeat to obtain all three classifiers (bacterial ARI, viral ARI and non-infectious ARI) within a specified platform matching the gene expression values.
- FIG. 2 is a diagram showing an example of generating and/or using classifiers in accordance with some embodiments of the present disclosure.
- FIG. 3 is a schematic showing a method of classification 20 of an etiology of acute respiratory symptoms suffered by a subject making use of classifiers according to some embodiments of the present disclosure.
- FIG. 4 presents schematics showing the decision pattern for using secondary classification to determine the etiology of an ARI in a subject in accordance with some embodiments of the present disclosure.
- FIG. 5 is a diagram of an example training method presented in Example 1.
- a cohort of patients encompassing bacterial ARI, viral ARI, or non-infectious illness was used to develop classifiers of each condition.
- This combined ARI classifier was validated using leave one out cross-validation and compared to three published classifiers of bacterial vs. viral infection.
- the combined ARI classifier was also externally validated in six publically available datasets. In one experiment, healthy volunteers were included in the training set to determine their suitability as “no-infection” controls. All subsequent experiments were performed without the use of this healthy subject cohort.
- FIG. 6 presents graphs showing the results of leave-one-out cross-validation of three classifiers (bacterial ARI, viral ARI and noninfectious illness) according an example training method presented in Example 1.
- Each patient is assigned probabilities of having bacterial ARI (triangle), viral ARI (circle), and non-infectious illness (square).
- Patients clinically adjudicated as having bacterial ARI, viral ARI, or non-infectious illness, are presented in the top, center, and bottom panels, respectively. Overall classification accuracy was 87%.
- FIG. 7 is a graph showing the evaluation of healthy adults as a no-infection control, rather than an ill-but-uninfected control. This figure demonstrates the unexpected superiority of the use of ill-but-not infected subjects as the control.
- FIG. 8 shows the positive and negative predictive values for A) Bacterial and B) Viral ARI classification as a function of prevalence.
- FIG. 9 is a Venn diagram representing overlap in the Bacterial ARI, Viral ARI, and Non-infectious Illness Classifiers. There are 71 genes in the Bacterial ARI Classifier, 33 in the Viral
- ARI Classifier and 26 in the Non-infectious Illness Classifier.
- One gene overlaps between the Bacterial and Viral ARI Classifiers.
- Five genes overlap between the Bacterial ARI and Non-infectious Illness Classifiers.
- Four genes overlap between the Viral ARI and Non-infectious Illness Classifiers.
- FIG. 10 is a graph showing Classifier performance in patients with co-infection by the identification of bacterial and viral pathogens.
- Subjects 1-6 have a bacterial host response.
- Subjects 7-9 have both bacterial and viral host responses which may indicate true co-infection.
- Subjects 10-23 have a viral host response.
- Subjects 24-25 do not have bacterial or viral host responses.
- FIG. 11 is a block diagram of a classification system and/or computer program product that may be used in a platform.
- a classification system and/or computer program product 1100 may include a processor subsystem 1140 , including one or more Central Processing Units (CPU) on which one or more operating systems and/or one or more applications run. While one processor 1140 is shown, it will be understood that multiple processors 1140 may be present, which may be either electrically interconnected or separate.
- Processor(s) 1140 are configured to execute computer program code from memory devices, such as memory 1150 , to perform at least some of the operations and methods described herein.
- the storage circuit 1170 may store databases which provide access to the data/parameters/classifiers used by the classification system 1110 such as the signatures, weights, thresholds, etc.
- An input/output circuit 1160 may include displays and/or user input devices, such as keyboards, touch screens and/or pointing devices. Devices attached to the input/output circuit 1160 may be used to provide information to the processor 1140 by a user of the classification system 1100 . Devices attached to the input/output circuit 1160 may include networking or communication controllers, input devices (keyboard, a mouse, touch screen, etc.) and output devices (printer or display).
- An optional update circuit 1180 may be included as an interface for providing updates to the classification system 1100 such as updates to the code executed by the processor 1140 that are stored in the memory 1150 and/or the storage circuit 1170 . Updates provided via the update circuit 1180 may also include updates to portions of the storage circuit 1170 related to a database and/or other data storage format which maintains information for the classification system 1100 , such as the signatures, weights, thresholds, etc.
- the sample input circuit 1110 provides an interface for the classification system 1100 to receive biological samples to be analyzed.
- the sample processing circuit 1120 may further process the biological sample within the classification system 1100 so as to prepare the biological sample for automated analysis.
- Articles “a” and “an” are used herein to refer to one or to more than one (i.e., at least one) of the grammatical object of the article.
- an element means at least one element and can include more than one element.
- the present disclosure provides that alterations in gene, protein and metabolite expression in blood in response to pathogen exposure that causes acute respiratory infections can be used to identify and characterize the etiology of the ARI in a subject with a high degree of accuracy.
- ARI refers to an infection, or an illness showing symptoms and/or physical findings consistent with an infection (e.g., symptoms such as coughing, wheezing, fever, sore throat, congestion; physical findings such as elevated heart rate, elevated breath rate, abnormal white blood cell count, low arterial carbon dioxide tension (PaCO 2 ), etc.), of the upper or lower respiratory tract, often due to a bacterial or viral pathogen, and characterized by rapid progression of symptoms over hours to days.
- ARIs may primarily be of the upper respiratory tract (URIs), the lower respiratory tract (LRIs), or a combination of the two. ARIs may have systemic effects due to spread of the infection beyond the respiratory tract or due to collateral damage induced by the immune response.
- An example of the former includes Staphylococcus aureus pneumonia that has spread to the blood stream and can result in secondary sites of infection, including endocarditis (infection of the heart valves), septic arthritis (joint infection), or osteomyelitis (bone infection).
- An example of the latter includes influenza pneumonia leading to acute respiratory distress syndrome and respiratory failure.
- signature refers to a set of biological analytes and the measurable quantities of said analytes whose particular combination signifies the presence or absence of the specified biological state. These signatures are discovered in a plurality of subjects with known status (e.g., with a confirmed respiratory bacterial infection, respiratory viral infection, or suffering from non-infectious illness), and are discriminative (individually or jointly) of one or more categories or outcomes of interest. These measurable analytes, also known as biological markers, can be (but are not limited to) gene expression levels, protein or peptide levels, or metabolite levels. See also US 2015/0227681 to Courchesne et al.; US 2016/0153993 to Eden et al.
- the “signature” is a particular combination of genes whose expression levels, when incorporated into a classifier as taught herein, discriminate a condition such as a bacterial ARI, viral ARI or non-infectious illness. See, for example, Table 1, Table 2, Table 9, Table 10 and Table 12 hereinbelow.
- the signature is agnostic to the species of respiratory virus or bacteria (i.e., while differentiating between virus or bacteria, it does not differentiate between particular genus or species of virus or bacteria) and/or agnostic to the particular cause of the non-infectious illness.
- classifier and “predictor” are used interchangeably and refer to a mathematical function that uses the values of the signature (e.g., gene expression levels for a defined set of genes) and a pre-determined coefficient (or weight) for each signature component to generate scores for a given observation or individual patient for the purpose of assignment to a category.
- the classifier may be linear and/or probabilistic.
- a classifier is linear if scores are a function of summed signature values weighted by a set of coefficients.
- a classifier is probabilistic if the function of signature values generates a probability, a value between 0 and 1.0 (or 0 and 100%) quantifying the likelihood that a subject or observation belongs to a particular category or will have a particular outcome, respectively.
- Probit regression and logistic regression are examples of probabilistic linear classifiers that use probit and logistic link functions, respectively, to generate a probability.
- a classifier as taught herein may be obtained by a procedure known as “training,” which makes use of a set of data containing observations with known category membership (e.g., bacterial ARI, viral ARI, and/or non-infection illness). See FIG. 1 .
- training seeks to find the optimal coefficient (i.e., weight) for each component of a given signature (e.g., gene expression level components), as well as an optimal signature, where the optimal result is determined by the highest achievable classification accuracy.
- Classification refers to a method of assigning a subject suffering from or at risk for acute respiratory symptoms to one or more categories or outcomes (e.g., a patient is infected with a pathogen or is not infected, another categorization may be that a patient is infected with a virus and/or infected with a bacterium). See FIG. 3 .
- a subject may be classified to more than one category, e.g., in case of bacterial and viral co-infection.
- the outcome, or category is determined by the value of the scores provided by the classifier, which may be compared to a cut-off or threshold value, confidence level, or limit. In other scenarios, the probability of belonging to a particular category may be given (e.g., if the classifier reports probabilities).
- the term “indicative” when used with gene expression levels means that the gene expression levels are up-regulated or down-regulated, altered, or changed compared to the expression levels in alternative biological states (e.g., bacterial ARI or viral ARI) or control.
- alternative biological states e.g., bacterial ARI or viral ARI
- indicator when used with protein levels means that the protein levels are higher or lower, increased or decreased, altered, or changed compared to the standard protein levels or levels in alternative biological states.
- subject and “patient” are used interchangeably and refer to any animal being examined, studied or treated. It is not intended that the present disclosure be limited to any particular type of subject.
- humans are the preferred subject, while in other embodiments non-human animals are the preferred subject, including, but not limited to, mice, monkeys, ferrets, cattle, sheep, goats, pigs, chicken, turkeys, dogs, cats, horses and reptiles.
- the subject is suffering from an ARI or is displaying ARI-like symptoms.
- Platinum” or “technology” as used herein refers to an apparatus (e.g., instrument and associated parts, computer, computer-readable media comprising one or more databases as taught herein, reagents, etc.) that may be used to measure a signature, e.g., gene expression levels, in accordance with the present disclosure.
- platforms include, but are not limited to, an array platform, a thermal cycler platform (e.g., multiplexed and/or real-time PCR platform), a nucleic acid sequencing platform, a hybridization and multi-signal coded (e.g., fluorescence) detector platform, etc., a nucleic acid mass spectrometry platform, a magnetic resonance platform, and combinations thereof.
- the platform is configured to measure gene expression levels semi-quantitatively, that is, rather than measuring in discrete or absolute expression, the expression levels are measured as an estimate and/or relative to each other or a specified marker or markers (e.g., expression of another, “standard” or “reference,” gene).
- semi-quantitative measuring includes “real-time PCR” by performing PCR cycles until a signal indicating the specified mRNA is detected, and using the number of PCR cycles needed until detection to provide the estimated or relative expression levels of the genes within the signature.
- a real-time PCR platform includes, for example, a TaqMan® Low Density Array (TLDA), in which samples undergo multiplexed reverse transcription, followed by real-time PCR on an array card with a collection of wells in which real-time PCR is performed. See Kodani et al. 2011, J. Clin. Microbial. 49(6):2175-2182.
- a real-time PCR platform also includes, for example, a Biocartis IdyllaTM sample-to-result technology, in which cells are lysed, DNA/RNA extracted and real-time PCR is performed and results detected.
- a magnetic resonance platform includes, for example, T2 Biosystems® T2 Magnetic Resonance (T2MR®) technology, in which molecular targets may be identified in biological samples without the need for purification.
- T2MR® T2 Magnetic Resonance
- arrays are interchangeable and refer to an arrangement of a collection of nucleotide sequences presented on a substrate. Any type of array can be utilized in the methods provided herein.
- arrays can be on a solid substrate (a solid phase array), such as a glass slide, or on a semi-solid substrate, such as nitrocellulose membrane.
- Arrays can also be presented on beads, i.e., a bead array. These beads are typically microscopic and may be made of, e.g., polystyrene.
- the array can also be presented on nanoparticles, which may be made of, e.g., particularly gold, but also silver, palladium, or platinum.
- the nucleotide sequences can be DNA, RNA, or any permutations thereof (e.g., nucleotide analogues, such as locked nucleic acids (LNAs), and the like). In some embodiments, the nucleotide sequences span exon/intron boundaries to detect gene expression of spliced or mature RNA species rather than genomic DNA.
- the nucleotide sequences can also be partial sequences from a gene, primers, whole gene sequences, non-coding sequences, coding sequences, published sequences, known sequences, or novel sequences.
- the arrays may additionally comprise other compounds, such as antibodies, peptides, proteins, tissues, cells, chemicals, carbohydrates, and the like that specifically bind proteins or metabolites.
- An array platform includes, for example, the TaqMan® Low Density Array (TLDA) mentioned above, and an Affymetrix® microarray platform.
- TLDA TaqMan® Low Density Array
- a hybridization and multi-signal coded detector platform includes, for example, NanoString nCounter® technology, in which hybridization of a color-coded barcode attached to a target-specific probe (e.g., corresponding to a gene expression transcript of interest) is detected; and Luminex® xMAP® technology, in which microsphere beads are color coded and coated with a target-specific (e.g., gene expression transcript) probe for detection; and Illumina® BeadArray, in which microbeads are assembled onto fiber optic bundles or planar silica slides and coated with a target-specific (e.g., gene expression transcript) probe for detection.
- NanoString nCounter® technology in which hybridization of a color-coded barcode attached to a target-specific probe (e.g., corresponding to a gene expression transcript of interest) is detected
- Luminex® xMAP® technology in which microsphere beads are color coded and coated with a target-specific (e.g., gene expression transcript) probe for detection
- a nucleic acid mass spectrometry platform includes, for example, the Ibis Biosciences Plex-ID® Detector, in which DNA mass spectrometry is used to detect amplified DNA using mass profiles.
- a thermal cycler platform includes, for example, the FilmArray® multiplex PCR system, which extract and purifies nucleic acids from an unprocessed sample and performs nested multiplex PCR; and the RainDrop Digital PCR System, which is a droplet-based PCR platform using microfluidic chips.
- computer readable medium refers to any device or system for storing and providing information (e.g., data and instructions) to a computer processor.
- Examples of computer readable media include, but are not limited to, DVDs, CDs hard disk drives, magnetic tape and servers for streaming media over networks, and applications, such as those found on smart phones and tablets.
- aspects of the present invention including data structures and methods may be stored on a computer readable medium. Processing and data may also be performed on numerous device types, including but not limited to, desk top and lap top computers, tablets, smart phones, and the like.
- a biological sample comprises any sample that may be taken from a subject that contains genetic material that can be used in the methods provided herein.
- a biological sample may comprise a peripheral blood sample.
- peripheral blood sample refers to a sample of blood circulating in the circulatory system or body taken from the system of body.
- Other samples may comprise those taken from the upper respiratory tract, including but not limited to, sputum, nasopharyngeal swab and nasopharyngeal wash.
- a biological sample may also comprise those samples taken from the lower respiratory tract, including but not limited to, bronchoalveolar lavage and endotracheal aspirate.
- a biological sample may also comprise any combinations thereof.
- genetic material refers to a material used to store genetic information in the nuclei or mitochondria of an organism's cells.
- examples of genetic material include, but are not limited to, double-stranded and single-stranded DNA, cDNA, RNA, and mRNA.
- plurality of nucleic acid oligomers refers to two or more nucleic acid oligomers, which can be DNA or RNA.
- treat refers to the reduction or amelioration of the severity, duration and/or progression of a disease or disorder or one or more symptoms thereof resulting from the administration of one or more therapies. Such terms refer to a reduction in the replication of a virus or bacteria, or a reduction in the spread of a virus or bacteria to other organs or tissues in a subject or to other subjects. Treatment may also include therapies for ARIs resulting from non-infectious illness, such as allergy treatment, asthma treatments, and the like.
- the term “effective amount” refers to an amount of a therapeutic agent that is sufficient to exert a physiological effect in the subject.
- response refers to a change in gene expression levels of genes in a subject in response to the subject being infected with a virus or bacteria or suffering from a non-infectious illness compared to the gene expression levels of the genes in a subject that is not infected with a virus, bacteria or suffering from a non-infectious illness or a control subject.
- a therapeutic agent for treating a subject having bacteremia is an antibiotic which include, but are not limited to, penicillins, cephalosporins, fluroquinolones, tetracyclines, macrolides, and aminoglycosides.
- a therapeutic agent for treating a subject having a viral respiratory infection includes, but is not limited to, oseltamivir, RNAi antivirals, inhaled ribavirin, monoclonal antibody respigam, zanamivir, and neuraminidase blocking agents.
- the invention contemplates the use of the methods of the invention to determine treatments with antivirals or antibiotics that are not yet available.
- Appropriate treatment regimes also include treatments for ARIs resulting from non-infectious illness, such as allergy treatments, including but not limited to, administration of antihistamines, decongestants, anticholinergic nasal sprays, leukotriene inhibitors, mast cell inhibitors, steroid nasal sprays, etc.; and asthma treatments, including, but not limited to, inhaled corticosteroids, leukotriene modifiers, long-acting beta agonists, combinations inhalers (e.g., fluticasone-salmeterol; budesonide-formoterol; mometasone-formoterol, etc.), theophylline, short-acting beta agonists, ipratropium, oral and intravenous corticosteroids, omalizumab, and the like.
- allergy treatments including but not limited to, administration of antihistamines, decongestants, anticholinergic nasal sprays, leukotriene inhibitors, mast cell inhibitors
- Such regimens require the act of administering to a subject a therapeutic agent(s) capable of producing reduction of symptoms associated with a disease state.
- therapeutic agents include, but are not limited to, NSAIDS, acetaminophen, anti-histamines, beta-agonists, anti-tussives or other medicaments that reduce the symptoms associated with the disease process.
- the present disclosure provides methods of generating classifiers (also referred to as training 10 ) for use in the methods of determining the etiology of an acute respiratory illness in a subject.
- Gene expression-based classifiers are developed that can be used to identify and characterize the etiology of an ARI in a subject with a high degree of accuracy.
- an acute respiratory infection (ARI) classifier comprising, consisting of, or consisting essentially of: (i) obtaining a biological sample (e.g., a peripheral blood sample) from a plurality of subjects suffering from bacterial, viral or non-infectious acute respiratory infection 100 ; (ii) optionally, isolating RNA from said sample (e.g., total RNA to create a transcriptome) ( 105 , not shown in FIG.
- a biological sample e.g., a peripheral blood sample
- RNA from said sample e.g., total RNA to create a transcriptome
- the sample is not purified after collection.
- the sample may be purified to remove extraneous material, before or after lysis of cells.
- the sample is purified with cell lysis and removal of cellular materials, isolation of nucleic acids, and/or reduction of abundant transcripts such as globin or ribosomal RNAs.
- measuring gene expression levels may include generating one or more microarrays using said transcriptomes; measuring said transcriptomes using a plurality of primers; analyzing and correcting batch differences.
- the method further includes uploading 140 the final gene target list for the generated classifier, the associated weights (w n ), and threshold values to one or more databases.
- FIG. 2 An example of generating said classifiers is detailed in FIG. 2 .
- biological samples from a cohort of patients encompassing bacterial ARI, viral ARI, or non-infectious illness are used to develop gene expression-based classifiers for each condition (i.e., bacterial acute respiratory infection, viral acute respiratory infection, or non-infectious cause of illness).
- the bacterial ARI classifier is obtained to positively identifying those with bacterial ARI vs. either viral ARI or non-infectious illnesses.
- the viral ARI classifier is obtained to positively identifying those with viral ARI vs. bacterial ARI or non-infectious illness (NI).
- the non-infectious illness classifier is generated to improve bacterial and viral ARI classifier specificity.
- signatures for bacterial ARI classifiers, viral ARI classifiers, and non-infectious illness classifiers are generated (e.g., by applying a sparse logistic regression model).
- the ARI classifier may then be combined, if desired, into a single classifier termed “the ARI classifier” by following a one-versus-all scheme whereby largest membership probability assigns class label. See also FIG. 5 .
- the combined ARI classifier may be validated in some embodiments using leave-one-out cross-validation in the same population from which it was derived and/or may be validated in some embodiments using publically available human gene expression datasets of samples from subjects suffering from illness of known etiology.
- validation may be performed using publically available human gene expression datasets (e.g., GSE6269, GSE42026, GSE40396, GSE20346, and/or GSE42834), the datasets chosen if they included at least two clinical groups (bacterial ARI, viral ARI, or non-infectious illness).
- GSE6269 e.g., GSE6269, GSE42026, GSE40396, GSE20346, and/or GSE42834
- the datasets chosen if they included at least two clinical groups bacterial ARI, viral ARI, or non-infectious illness.
- the classifier may be validated in a standard set of samples from subjects suffering from illness of known etiology, i.e., bacterial ARI, viral ARI, or non-infectious illness.
- the methods and assays of the present disclosure may be based upon gene expression, for example, through direct measurement of RNA, measurement of derived materials (e.g., cDNA), and measurement of RNA products (e.g., encoded proteins or peptides). Any method of extracting and screening gene expression may be used and is within the scope of the present disclosure.
- the measuring comprises the detection and quantification (e.g., semi-quantification) of mRNA in the sample.
- the gene expression levels are adjusted relative to one or more standard gene level(s) (“normalized”). As known in the art, normalizing is done to remove technical variability inherent to a platform to give a quantity or relative quantity (e.g., of expressed genes).
- detection and quantification of mRNA may first involve a reverse transcription and/or amplification step, e.g., RT-PCR such as quantitative RT-PCR.
- detection and quantification may be based upon the unamplified mRNA molecules present in or purified from the biological sample.
- Direct detection and measurement of RNA molecules typically involves hybridization to complementary primers and/or labeled probes.
- Such methods include traditional northern blotting and surface-enhanced Raman spectroscopy (SERS), which involves shooting a laser at a sample exposed to surfaces of plasmonic-active metal structures with gene-specific probes, and measuring changes in light frequency as it scatters.
- SERS surface-enhanced Raman spectroscopy
- RNA derivatives typically involves hybridization to complementary primers and/or labeled probes.
- This may include high-density oligonucleotide probe arrays (e.g., solid state microarrays and bead arrays) or related probe-hybridization methods, and polymerase chain reaction (PCR)-based amplification and detection, including real-time, digital, and end-point PCR methods for relative and absolute quantitation of specific RNA molecules.
- PCR polymerase chain reaction
- sequencing-based methods can be used to detect and quantify RNA or
- RNA-derived material levels When applied to RNA, sequencing methods are referred to as RNAseq, and provide both qualitative (sequence, or presence/absence of an RNA, or its cognate cDNA, in a sample) and quantitative (copy number) information on RNA molecules from a sample. See, e.g., Wang et al. 2009 Nat. Rev. Genet. 10(1):57-63.
- Another sequence-based method serial analysis of gene expression (SAGE), uses cDNA “tags” as a proxy to measure expression levels of RNA molecules.
- mRNA detection and quantification may also be used to complete the methods of the present disclosure.
- PixelTM System incorporating Molecular IndexingTM, developed by CELLULAR RESEARCH, INC., NanoString® Technologies nCounter gene expression system
- mRNA-Seq Molecular Indexing
- Tag-Profiling Tag-Profiling
- BeadArrayTM technology VeraCode from Illumina
- VeraCode VeraCode from Illumina
- ICEPlex System from PrimeraDx
- QuantiGene 2.0 Multiplex Assay from Affymetrix.
- RNA from whole blood from a subject can be collected using RNA preservation reagents such as PAXgeneTM RNA tubes (PreAnalytiX, Valencia, Calif.).
- the RNA can be extracted using a standard PAXgeneTM or VersageneTM (Gentra Systems, Inc, Minneapolis, Minn.) RNA extraction protocol.
- the VersageneTM kit produces greater yields of higher quality RNA from the PAXgeneTM RNA tubes.
- GLOBINCIearTM Ambion, Austin, Tex.
- RNA quality can be assessed using an Agilent 2100 Bioanalyzer immediately following extraction. This analysis provides an RNA Integrity Number (RIN) as a quantitative measure of RNA quality. Also, following globin reduction the samples can be compared to the globin-reduced standards. In addition, the scaling factors and background can be assessed following hybridization to microarrays.
- RIN RNA Integrity Number
- Real-time PCR may be used to quickly identify gene expression from a whole blood sample.
- the isolated RNA can be reverse transcribed and then amplified and detected in real time using non-specific fluorescent dyes that intercalate with the resulting ds-DNA, or sequence-specific DNA probes labeled with a fluorescent reporter which permits detection only after hybridization of the probe with its complementary DNA target.
- the expression levels are typically normalized following detection and quantification as appropriate for the particular platform using methods routinely practiced by those of ordinary skill in the art.
- the individual categories of classifiers are formed from a cohort inclusive of a variety of such causes thereof.
- the bacterial ARI classifier is obtained from a cohort having bacterial infections from multiple bacterial genera and/or species
- the viral ARI classifier is obtained from a cohort having viral infections from multiple viral genera and/or species
- the non-infectious illness classifier is obtained from a cohort having a non-infectious illness due to multiple non-infectious causes. See, e.g., Table 8.
- the respective classifiers obtained are agnostic to the underlying bacteria, virus, and non-infectious cause.
- some or all of the subjects with non-infectious causes of illness in the cohort have symptoms consistent with a respiratory infection.
- the signatures may be obtained using a supervised statistical approach known as sparse linear classification in which sets of genes are identified by the model according to their ability to separate phenotypes during a training process that uses the selected set of patient samples.
- the outcomes of training are gene signatures and classification coefficients for the three comparisons. Together the signatures and coefficients provide a classifier or predictor.
- Training may also be used to establish threshold or cut-off values. Threshold or cut-off values can be adjusted to change test performance, e.g., test sensitivity and specificity. For example, the threshold for bacterial ARI may be intentionally lowered to increase the sensitivity of the test for bacterial infection, if desired.
- the classifier generating comprises iteratively: (i) assigning a weight for each normalized gene expression value, entering the weight and expression value for each gene into a classifier (e.g., a linear regression classifier) equation and determining a score for outcome for each of the plurality of subjects, then (ii) determining the accuracy of classification for each outcome across the plurality of subjects, and then (iii) adjusting the weight until accuracy of classification is optimized.
- a classifier e.g., a linear regression classifier
- the classifier is a linear regression classifier and said generating comprises converting a score of said classifier to a probability using a link function.
- the link function specifies the link between the target/output of the model (e.g., probability of bacterial infection) and systematic components (in this instance, the combination of explanatory variables that comprise the predictor) of the linear model. It says how the expected value of the response relates to the linear predictor of explanatory variable.
- the present disclosure further provides methods for determining whether a patient has a respiratory illness due to a bacterial infection, a viral infection, or a non-infectious cause.
- the method for making this determination relies upon the use of classifiers obtained as taught herein.
- the methods may include: a) measuring the expression levels of pre-defined sets of genes (i.e., for one or more of the three signatures); b) normalizing gene expression levels for the technology used to make said measurement; c) taking those values and entering them into a bacterial classifier, a viral classifier and/or non-infectious illness classifier (i.e., predictors) that have pre-defined weighting values (coefficients) for each of the genes in each signature; d) comparing the output of the classifiers to pre-defined thresholds, cut-off values, confidence intervals or ranges of values that indicate likelihood of infection; and optionally e) jointly reporting the results of the classifiers.
- each of the three gene signatures is informative of the patient's host response to a different ARI etiology (bacterial or viral) or to an ill, but not infected, state (NI).
- ARI etiology bacterial or viral
- NI ill, but not infected, state
- These signatures are groups of gene transcripts which have consistent and coordinated increased or decreased levels of expression in response to one of three clinical states: bacterial ARI, viral ARI, or a non-infected but ill state.
- These signatures are derived using carefully adjudicated groups of patient samples with the condition(s) of interest (training 10 ).
- the mRNA is extracted.
- the mRNA (or a defined region of each mRNA), is quantified for all, or a subset, of the genes in the signatures.
- the mRNA may have to be first purified from the sample.
- the signature is reflective of a clinical state and is defined relative to at least one of the other two possibilities.
- the bacterial ARI signature is identified as a group of biomarkers (here, represented by gene mRNA transcripts) that distinguish patients with bacterial ARI and those without bacterial ARI (including patients with viral ARI or non-infectious illness as it pertains to this application).
- the viral ARI signature is defined by a group of biomarkers that distinguish patients with viral ARI from those without viral ARI (including patients with either bacterial ARI or non-infectious illness).
- the non-infectious illness signature is defined by a group of biomarkers that distinguish patients with non-infectious causes of illness relative to those with either bacterial or viral ARI.
- the normalized expression levels of each gene of the signature are the explanatory or independent variables or features used in the classifier.
- the classifier may have a general form as a probit regression formulation:
- ⁇ ( ⁇ ) is the probit (or logistic, etc.) link function
- ⁇ 1 , ⁇ 2 , . . . , ⁇ d ⁇ are the coefficients obtained during training (e.g., second, third and fourth columns from Table 9) (coefficients may also be denoted ⁇ w 1 ,w 2 , . . . , w d ⁇ as “weights” herein);
- ⁇ X 1 ,X 2 , . . . , X d ⁇ are the normalized gene expression levels of the signature; and d is the size of the signature (i.e., number of genes).
- the value of the coefficients for each explanatory variable will change for each technology platform used to measure the expression of the genes or a subset of genes used in the probit regression model.
- the coefficients for each of the features in the classifier algorithm are shown in Table 9.
- the sensitivity, specificity, and overall accuracy of each classifier may be optimized by changing the threshold for classification using receiving operating characteristic (ROC) curves.
- ROC operating characteristic
- Another aspect of the present disclosure provides a method for determining whether an acute respiratory infection (ARI) in a subject is bacterial in origin, viral in origin, or non-infectious in origin comprising, consisting of, or consisting essentially of a) obtaining a biological sample from the subject; b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes (i.e., three signatures); c) normalizing gene expression levels for the technology used to make said measurement to generate a normalized value; d) entering the normalized value into a bacterial classifier, a viral classifier and non-infectious illness classifier (i.e., predictors) that have pre-defined weighting values (coefficients) for each of the genes in each signature; e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; and e) classifying the sample as being of bacterial etiology, viral etiology
- the classifiers that are developed during training and using a training set of samples are applied for prediction purposes to diagnose new individuals (“classification”). For each subject or patient, a biological sample is taken and the normalized levels of expression (i.e., the relative amount of mRNA expression) in the sample of each of the genes specified by the signatures found during training are the input for the classifiers. The classifiers also use the weighting coefficients discovered during training for each gene. As outputs, the classifiers are used to compute three probability values. Each probability value may be used to determine the likelihood of the three considered clinical states: bacterial ARI, viral ARI, and non-infectious illness.
- the results of each of the classifiers are reported.
- the three signatures with their corresponding coefficients are applied to an individual patient to obtain three probability values, namely probability of having a bacterial ARI, viral ARI, and a non-infectious illness. In some embodiments, these values may be reported relative to a reference range that indicates the confidence with which the classification is made.
- the output of the classifier may be compared to a threshold value, for example, to report a “positive” in the case that the classifier score or probability exceeds the threshold indicating the presence of one or more of a bacterial ARI, viral ARI, or non-infectious illness. If the classifier score or probability fails to reach the threshold, the result would be reported as “negative” for the respective condition.
- the values for bacterial and viral ARI alone are reported and the report is silent on the likelihood of ill but not infected.
- a classifier obtained with one platform may not show optimal performance on another platform. This could be due to the promiscuity of probes or other technical issues particular to the platform. Accordingly, also described herein are methods to adapt a signature as taught herein from one platform for another.
- a signature obtained from an Affymetrix platform may be adapted to a TLDA platform by the use of corresponding TLDA probes for the genes in the signature and/or substitute genes correlated with those in the signature, for the Affymetrix platform.
- Table 1 shows a list of Affymetrix probes and the genes they measure, plus “replacement genes” that are introduced as replacements for gene probes that either may not perform well on the TLDA platform for technical reasons or to replace those Affymetrix probes for which there is no cognate TLDA probe. These replacements may indicate highly correlated genes or may be probes that bind to a different location in the same gene transcript. Additional genes may be included, such as pan-viral gene probes.
- the weights shown in Table 1 are weights calculated for a classifier implemented on the microarray platform. Weights that have not been estimated are indicated by “NA” in the table. (Example 4 below provides the completed translation of these classifiers to the TLDA platform.)
- Reference probes for TLDA i.e., normalization genes, e.g., TRAP1, PPIB, GAPDH and 18S
- TLDA normalization genes, e.g., TRAP1, PPIB, GAPDH and 18S
- Affymetrix probeset ID are not part of the classifier.
- Additional gene probes that do not necessarily correspond to the Affymetrix probeset also have “NA” in the Affymetrix probeset ID column.
- This method of determining the etiology of an ARI may be combined with other tests. For example, if the patient is determined to have a viral ARI, a follow-up test may be to determine if influenza A or B can be directly detected or if a host response indicative of such an infection can be detected. Similarly, a follow-up test to a result of bacterial ARI may be to determine if a Gram positive or a Gram negative bacterium can be directly detected or if a host response indicative of such an infection can be detected. In some embodiments, simultaneous testing may be performed to determine the class of infection using the classifiers, and also to test for specific pathogens using pathogen-specific probes or detection methods. See, e.g., US 2015/0284780 to Eley et al. (method for detecting active tuberculosis); US 2014/0323391 to Tsalik et al. (method for classification of bacterial infection).
- an acute respiratory infection (ARI) in a subject is bacterial in origin, viral in origin, or non-infectious in origin
- a method for determining whether an acute respiratory infection (ARI) in a subject is bacterial in origin, viral in origin, or non-infectious in origin comprising, consisting of, or consisting essentially of (a) obtaining a biological sample from the subject; (b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes (i.e., three signatures); (c) normalizing gene expression levels as required for the technology used to make said measurement to generate a normalized value; (d) entering the normalized value into classifiers (i.e., predictors) that have pre-defined weighting values (coefficients) for each of the genes in each signature; (e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; (f) if the sample is negative for bacteria, repeating step (d
- Another aspect of the present provides a method for determining whether an acute respiratory infection (ARI) in a subject is bacterial in origin, viral in origin, or non-infectious in origin comprising, consisting of, or consisting essentially of (a) obtaining a biological sample from the subject; (b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes (i.e., three signatures); (c) normalizing gene expression levels for the technology used to make said measurement to generate a normalized value; (d) entering the normalized value into classifiers (i.e., predictors) that have pre-defined weighting values (coefficients) for each of the genes in each signature; (e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; (f) if the sample is negative for virus, repeating step (d) using only the bacteria classifier and non-infectious classifier; and (g) classifying the sample as being of
- Yet another aspect of the present provides a method for determining whether an acute respiratory infection (ARI) in a subject is bacterial in origin, viral in origin, or non-infectious in origin comprising, consisting of, or consisting essentially of (a) obtaining a biological sample from the subject; (b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes (i.e., three signatures); (c) normalizing gene expression levels for the technology used to make said measurement to generate a normalized value; (d) entering the normalized value into classifiers (i.e., predictors) that have pre-defined weighting values (coefficients) for each of the genes in each signature; (e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; (f) if the sample is negative for non-infectious illness, repeating step (d) using only the viral classifier and bacterial classifier; and (g) classifying the sample
- the method further comprises generating a report assigning the patient a score indicating the probability of the etiology of the ARI.
- Classifying the status of a patient using a secondary classification scheme is shown in FIG. 4 .
- the bacterial ARI classifier will distinguish between patients with a bacterial ARI from those without a bacterial ARI, which could, instead, be a viral ARI or a non-infectious cause of illness.
- a secondary classification can then be imposed on those patients with non-bacterial ARI to further discriminate between viral ARI and non-infectious illness.
- This same process of primary and secondary classification can also be applied to the viral ARI classifier where patients determined not to have a viral infection would then be secondarily classified as having a bacterial ARI or non-infectious cause of illness.
- applying the non-infectious illness classifier as a primary test will determine whether patients have such a non-infectious illness or instead have an infectious cause of symptoms.
- the secondary classification step would determine if that infectious is due to bacterial or viral pathogens.
- Results from the three primary and three secondary classifications can be summed through various techniques by those skilled in the art (such as summation, counts, or average) to produce an actionable report for the provider.
- the genes used for this secondary level of classification can be some or all of those presented in Table 2.
- the three classifiers described above are used to perform the 1 st level classification. Then for those patients with non-bacterial infection, a secondary classifier is defined to distinguish viral ARI from those with non-infectious illness ( FIG. 4 , left panel). Similarly, for those patients with non-viral infection, a new classifier is used to distinguish viral from non-infectious illness ( FIG. 4 , middle panel), and for those patients who are not classified as having a non-infectious illness in the first step, a new classifier is used to distinguish between viral and bacterial ARI ( FIG. 4 , right panel).
- nine probabilities may be generated, and those probabilities may be combined in a number of ways.
- Two strategies are described here as a way to reconcile the three sets of predictions, where each has a probability of bacterial ARI, viral ARI, and non-infectious illness.
- Highest predicted average probability All predicted probabilities for bacterial ARI are averaged, as are all the predicted probabilities of viral ARI and, similarly, all predicted probabilities of non-infectious illness. The greatest averaged probability denotes the diagnosis.
- the Result of Tier 1 classification could be, for example (clinical classification presented in rows; diagnostic test prediction presented in columns) similar to that presented in Table 3.
- Classification can be achieved, for example, as described above, and/or as summarized in Table 2.
- Table 2 summarizes the gene membership in three distinct classification strategies that solve different diagnostic questions. There are a total of 270 probes that collectively comprise three complex classifiers. The first is referred to as BVS (Bacterial ARI, Viral ARI, SIRS), which is the same as that presented below in Example 1. These probes are the same as those presented in Table 9, which offers probe/gene weights used in classification. They also correspond to the genes presented in Table 10.
- the second is referred to as 2L for 2-layer or 2-tier. This is the hierarchical scheme presented in FIG. 4 .
- the third is a one-tier classification scheme, BVSH, which is similar to BVS but also includes a population of healthy controls (similarly described in Example 1).
- This group has been shown to be a poor control for non-infection, but there are use cases in which discrimination from healthy may be clinically important. For example, this can include the serial measurement of signatures to correlate with convalescence. It may also be used to discriminate patients who have been exposed to an infectious agent and are presymptomatic vs. asymptomatic.
- four groups are represented in the training cohort—those with bacterial ARI, viral ARI, SIRS (non-infectious illness), and Healthy. These four groups are used to generate four distinct signatures that distinguish each class from all other possibilities.
- BVSH refers to a one-level classification scheme that includes healthy individuals in the training cohort and therefore includes a classifier for the healthy state as compared to bacterial ARI, viral ARI, or non-infectious illness.
- the dark grey BVSH column identifies any gene or probe included in this classification scheme.
- This scheme is itself comprised by BVSH-BO, BVSH-VO, BVSH-SO, and BVSH-HO with their respective probe/gene compositions denoted by ‘1’ in these columns.
- Table 2 provides a summary of use of members of the gene sets for viral, bacterial, and non-infectious illness classifiers that are constructed according to the required task.
- a ‘1’ indicates membership of the gene in the classifier.
- Another aspect of the present disclosure provides a method of treating an acute respiratory infection (ARI) whose etiology is unknown in a subject, said method comprising, consisting of, or consisting essentially of (a) obtaining a biological sample from the subject; (b) determining the gene expression profile of the subject from the biological sample by evaluating the expression levels of pre-defined sets of genes (e.g., one, two or three or more signatures); (c) normalizing gene expression levels as required for the technology used to make said measurement to generate a normalized value; (d) entering the normalized value into a bacterial classifier, a viral classifier and non-infectious illness classifier (i.e., predictors) that have pre-defined weighting values (coefficients) for each of the genes in each signature; (e) comparing the output of the classifiers to pre-defined thresholds, cut-off values, or ranges of values that indicate likelihood of infection; (f) classifying the sample as being of bacterial etiology, viral etiology,
- step (g) comprises administering an antibacterial therapy when the etiology of the ARI is determined to be bacterial. In other embodiments, step (g) comprises administering an antiviral therapy when the etiology of the ARI is determined to be viral.
- ARI etiology of the ARI of the subject
- she may undergo treatment, for example anti-viral therapy if the ARI is determined to be viral, and/or she may be quarantined to her home for the course of the infection.
- bacterial therapy regimens may be administered (e.g., administration of antibiotics) if the ARI is determined to be bacterial.
- Those subjects classified as non-infectious illness may be sent home or seen for further diagnosis and treatment (e.g., allergy, asthma, etc.).
- the person performing the peripheral blood sample need not perform the comparison, however, as it is contemplated that a laboratory may communicate the gene expression levels of the classifiers to a medical practitioner for the purpose of identifying the etiology of the ARI and for the administration of appropriate treatment. Additionally, it is contemplated that a medical professional, after examining a patient, would order an agent to obtain a peripheral blood sample, have the sample assayed for the classifiers, and have the agent report patient's etiological status to the medical professional. Once the medical professional has obtained the etiology of the ARI, the medical professional could order suitable treatment and/or quarantine.
- the methods provided herein can be effectively used to diagnose the etiology of illness in order to correctly treat the patient and reduce inappropriate use of antibiotics. Further, the methods provided herein have a variety of other uses, including but not limited to, (1) a host-based test to detect individuals who have been exposed to a pathogen and have impending, but not symptomatic, illness (e.g., in scenarios of natural spread of diseases through a population but also in the case of bioterrorism); (2) a host-based test for monitoring response to a vaccine or a drug, either in a clinical trial setting or for population monitoring of immunity; (3) a host-based test for screening for impending illness prior to deployment (e.g., a military deployment or on a civilian scenario such as embarkation on a cruise ship); and (4) a host-based test for the screening of livestock for ARIs (e.g., avian flu and other potentially pandemic viruses).
- a host-based test to detect individuals who have been exposed to a pathogen and have impending, but not symptomatic,
- kits for determining the etiology of an acute respiratory infection (ARI) in a subject comprising, consisting of, or consisting essentially of (a) a means for extracting a biological sample; (b) a means for generating one or more arrays consisting of a plurality of synthetic oligonucleotides with regions homologous to a group of gene transcripts as taught herein; and (c) instructions for use.
- Yet another aspect of the present disclosure provides a method of using a kit for assessing the acute respiratory infection (ARI) classifier comprising, consisting of, or consisting essentially of: (a) generating one or more arrays consisting of a plurality of synthetic oligonucleotides with regions homologous to a a group of gene transcripts as taught herein; (b) adding to said array oligonucleotides with regions homologous to normalizing genes; (c) obtaining a biological sample from a subject suffering from an acute respiratory infection (ARI); (d) isolating RNA from said sample to create a transcriptome; (e) measuring said transcriptome on said array; (f) normalizing the measurements of said transcriptome to the normalizing genes, electronically transferring normalized measurements to a computer to implement the classifier algorithm(s), (g) generating a report; and optionally (h) administering an appropriate treatment based on the results.
- ARI acute respiratory infection
- a classification system and/or computer program product 1100 may be used in or by a platform, according to various embodiments described herein.
- a classification system and/or computer program product 1100 may be embodied as one or more enterprise, application, personal, pervasive and/or embedded computer systems that are operable to receive, transmit, process and store data using any suitable combination of software, firmware and/or hardware and that may be standalone and/or interconnected by any conventional, public and/or private, real and/or virtual, wired and/or wireless network including all or a portion of the global communication network known as the Internet, and may include various types of tangible, non-transitory computer readable medium.
- the classification system 1100 may include a processor subsystem 1140 , including one or more Central Processing Units (CPU) on which one or more operating systems and/or one or more applications run. While one processor 1140 is shown, it will be understood that multiple processors 1140 may be present, which may be either electrically interconnected or separate. Processor(s) 1140 are configured to execute computer program code from memory devices, such as memory 1150 , to perform at least some of the operations and methods described herein, and may be any conventional or special purpose processor, including, but not limited to, digital signal processor (DSP), field programmable gate array (FPGA), application specific integrated circuit (ASIC), and multi-core processors.
- DSP digital signal processor
- FPGA field programmable gate array
- ASIC application specific integrated circuit
- the memory subsystem 1150 may include a hierarchy of memory devices such as Random Access Memory (RAM), Read-Only Memory (ROM), Erasable Programmable Read-Only Memory (EPROM) or flash memory, and/or any other solid state memory devices.
- RAM Random Access Memory
- ROM Read-Only Memory
- EPROM Erasable Programmable Read-Only Memory
- flash memory any other solid state memory devices.
- a storage circuit 1170 may also be provided, which may include, for example, a portable computer diskette, a hard disk, a portable Compact Disk Read-Only Memory (CDROM), an optical storage device, a magnetic storage device and/or any other kind of disk- or tape-based storage subsystem.
- the storage circuit 1170 may provide non-volatile storage of data/parameters/classifiers for the classification system 1100 .
- the storage circuit 1170 may include disk drive and/or network store components.
- the storage circuit 1170 may be used to store code to be executed and/or data to be accessed by the processor 1140 .
- the storage circuit 1170 may store databases which provide access to the data/parameters/classifiers used for the classification system 1110 such as the signatures, weights, thresholds, etc. Any combination of one or more computer readable media may be utilized by the storage circuit 1170 .
- the computer readable media may be a computer readable signal medium or a computer readable storage medium.
- a computer readable storage medium may be, for example, but not limited to, an electronic, magnetic, optical, electromagnetic, infrared, or semiconductor system, apparatus, or device, or any suitable combination of the foregoing.
- a computer readable storage medium may be any tangible medium that can contain, or store a program for use by or in connection with an instruction execution system, apparatus, or device.
- An input/output circuit 1160 may include displays and/or user input devices, such as keyboards, touch screens and/or pointing devices. Devices attached to the input/output circuit 1160 may be used to provide information to the processor 1140 by a user of the classification system 1100 . Devices attached to the input/output circuit 1160 may include networking or communication controllers, input devices (keyboard, a mouse, touch screen, etc.) and output devices (printer or display). The input/output circuit 1160 may also provide an interface to devices, such as a display and/or printer, to which results of the operations of the classification system 1100 can be communicated so as to be provided to the user of the classification system 1100 .
- An optional update circuit 1180 may be included as an interface for providing updates to the classification system 1100 . Updates may include updates to the code executed by the processor 1140 that are stored in the memory 1150 and/or the storage circuit 1170 . Updates provided via the update circuit 1180 may also include updates to portions of the storage circuit 1170 related to a database and/or other data storage format which maintains information for the classification system 1100 , such as the signatures, weights, thresholds, etc.
- the sample input circuit 1110 of the classification system 1100 may provide an interface for the platform as described hereinabove to receive biological samples to be analyzed.
- the sample input circuit 1110 may include mechanical elements, as well as electrical elements, which receive a biological sample provided by a user to the classification system 1100 and transport the biological sample within the classification system 1100 and/or platform to be processed.
- the sample input circuit 1110 may include a bar code reader that identifies a bar-coded container for identification of the sample and/or test order form.
- the sample processing circuit 1120 may further process the biological sample within the classification system 1100 and/or platform so as to prepare the biological sample for automated analysis.
- the sample analysis circuit 1130 may automatically analyze the processed biological sample.
- the sample analysis circuit 1130 may be used in measuring, e.g., gene expression levels of a pre-defined set of genes with the biological sample provided to the classification system 1100 .
- the sample analysis circuit 1130 may also generate normalized gene expression values by normalizing the gene expression levels.
- the sample analysis circuit 1130 may retrieve from the storage circuit 1170 a bacterial acute respiratory infection (ARI) classifier, a viral ARI classifier and a non-infectious illness classifier, these classifier(s) comprising pre-defined weighting values (i.e., coefficients) for each of the genes of the pre-defined set of genes.
- ARI bacterial acute respiratory infection
- the sample analysis circuit 1130 may enter the normalized gene expression values into one or more acute respiratory illness classifiers selected from the bacterial acute respiratory infection (ARI) classifier, the viral ARI classifier and the non-infectious illness classifier.
- the sample analysis circuit 1130 may calculate an etiology probability for one or more of a bacterial ARI, viral ARI and non-infectious illness based upon said classifier(s) and control output, via the input/output circuit 1160 , of a determination whether the acute respiratory illness in the subject is bacterial in origin, viral in origin, non-infectious in origin, or some combination thereof.
- the sample input circuit 1110 , the sample processing circuit 1120 , the sample analysis circuit 1130 , the input/output circuit 1160 , the storage circuit 1170 , and/or the update circuit 1180 may execute at least partially under the control of the one or more processors 1140 of the classification system 1100 .
- executing “under the control” of the processor 1140 means that the operations performed by the sample input circuit 1110 , the sample processing circuit 1120 , the sample analysis circuit 1130 , the input/output circuit 1160 , the storage circuit 1170 , and/or the update circuit 1180 may be at least partially executed and/or directed by the processor 1140 , but does not preclude at least a portion of the operations of those components being separately electrically or mechanically automated.
- the processor 1140 may control the operations of the classification system 1100 , as described herein, via the execution of computer program code.
- Computer program code for carrying out operations for aspects of the present disclosure may be written in any combination of one or more programming languages, including an object oriented programming language such as Java, Scala, Smalltalk, Eiffel, JADE, Emerald, C++, C#, VB.NET, Python or the like, conventional procedural programming languages, such as the “C” programming language, Visual Basic, Fortran 2003, Perl, COBOL 2002, PHP, ABAP, dynamic programming languages such as Python, Ruby and Groovy, or other programming languages.
- the program code may execute entirely on the classification system 1100 , partly on the classification system 1100 , as a stand-alone software package, partly on the classification system 1100 and partly on a remote computer or entirely on the remote computer or server.
- the remote computer may be connected to the classification system 1100 through any type of network, including a local area network (LAN) or a wide area network (WAN), or the connection may be made to an external computer (for example, through the Internet using an Internet Service Provider) or in a cloud computer environment or offered as a service such as a Software as a Service (SaaS).
- LAN local area network
- WAN wide area network
- SaaS Software as a Service
- the system includes computer readable code that can transform quantitative, or semi-quantitative, detection of gene expression to a cumulative score or probability of the etiology of the ARI.
- the system is a sample-to-result system, with the components integrated such that a user can simply insert a biological sample to be tested, and some time later (preferably a short amount of time, e.g., 30 or 45 minutes, or 1, 2, or 3 hours, up to 8, 12, 24 or 48 hours) receive a result output from the system.
- some time later preferably a short amount of time, e.g., 30 or 45 minutes, or 1, 2, or 3 hours, up to 8, 12, 24 or 48 hours
- any numerical range recited herein includes all values from the lower value to the upper value. For example, if a concentration range is stated as 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification. These are only examples of what is specifically intended, and all possible combinations of numerical values between and including the lowest value and the highest value enumerated are to be considered to be expressly stated in this application.
- Acute respiratory infections due to bacterial or viral pathogens are among the most common reasons for seeking medical care.
- Current pathogen-based diagnostic approaches are not reliable or timely, thus most patients receive inappropriate antibiotics.
- Host response biomarkers offer an alternative diagnostic approach to direct antimicrobial use.
- the samples that formed the basis for discovery were drawn from an observational, cohort study conducted at four tertiary care hospital emergency departments and a student health facility. 44 healthy controls and 273 patients with community-onset acute respiratory infection or non-infectious illness were selected from a larger cohort of patients with suspected sepsis (CAPSOD study). Mean age was 45 years and 45% of participants were male. Further demographic information may be found in Table 1 of Tsalik et al. (2016) Sci Transl Med 9(322):1-9, which is incorporated by reference herein.
- Clinical phenotypes were adjudicated through manual chart review. Routine microbiological testing and multiplex PCR for respiratory viral pathogens were performed. Peripheral whole blood gene expression was measured using microarrays. Sparse logistic regression was used to develop classifiers of bacterial vs. viral vs. non-infectious illness. Five independently derived datasets including 328 individuals were used for validation.
- Gene expression-based classifiers were developed for bacterial acute respiratory infection (71 probes), viral acute respiratory infection (33 probes), or a non-infectious cause of illness (26 probes). The three classifiers were applied to 273 patients where class assignment was determined by the highest predicted probability. Overall accuracy was 87% (23 8/273 concordant with clinical adjudication), which was more accurate than procalcitonin (78%, p ⁇ 0.03) and three published classifiers of bacterial vs. viral infection (78-83%). The classifiers developed here externally validated in five publicly available datasets (AUC 0.90-0.99). We compared the classification accuracy of the host gene expression-based tests to procalcitonin and clinically adjudicated diagnoses, which included bacterial or viral acute respiratory infection or non-infectious illness.
- the host's peripheral blood gene expression response to infection offers a diagnostic strategy complementary to those already in use. 8 This strategy has successfully characterized the host response to viral 8-13 and bacterial ARI 11,14 . Despite these advances, several issues preclude their use as diagnostics in patient care settings. An important consideration in the development of host-based molecular signatures is that they be developed in the intended use population. 15 However, nearly all published gene expression-based ARI classifiers used healthy individuals as controls and focused on small or homogeneous populations and are thus not optimized for use in acute care settings where patients present with undifferentiated symptoms. Furthermore, the statistical methods used to identify gene-expression classifiers often include redundant genes based on clustering, univariate testing, or pathway association. These strategies identify relevant biology but do not maximize diagnostic performance. An alternative, as exemplified here, is to combine genes from unrelated pathways to generate a more informative classifier.
- ARI cases included patients with upper or lower respiratory tract symptoms, as adjudicated by emergency medicine (SWG, EBQ) or infectious diseases (ELT) physicians.
- Adjudications were based on retrospective, manual chart reviews performed at least 28 days after enrollment and prior to any gene expression-based categorization, using previously published criteria. 17 The totality of information used to support these adjudications would not have been available to clinicians at the time of their evaluation. Seventy patients with microbiologically confirmed bacterial ARI were identified including four with pharyngitis and 66 with pneumonia.
- This panel detects influenza A and B, adenovirus (B, E), parainfluenza 1-4, respiratory syncytial virus A and B, human metapneumovirus, human rhinovirus, coronavirus (229E, OC43, NL63, HKU1), coxsackie/echo virus, and bocavirus.
- the transcriptomes of 317 subjects (273 ill patients and 44 healthy volunteers) were measured in two microarray batches with seven overlapping samples (GSE63990). Exploratory principal component analysis and hierarchical clustering revealed substantial batch differences. These were corrected by first estimating and removing probe-wise mean batch effects using the Bayesian fixed effects model. Next, we fitted a robust linear regression model with Huber loss function using seven overlapping samples, which was used to adjust the remaining expression values.
- Sparse classification methods such as sparse logistic regression perform classification and variable selection simultaneously while reducing over-fitting risk. 21 Therefore, separate gene selection strategies such as univariate testing or sparse factor models are unnecessary.
- a sparse logistic regression model was fitted independently to each of the binary tasks using the 40% of probes with the largest variance after batch correction. 22 Specifically, we used a Lasso regularized generalized linear model with binomial likelihood with nested cross-validation to select for the regularization parameters. Code was written in Matlab using the Glmnet toolbox. This generated Bacterial ARI, Viral ARI, and Non-Infectious Illness classifiers. Provided that each binary classifier estimates class membership probabilities (e.g., probability of bacterial vs.
- Classification performance metrics included area-under-the-receiving-operating-characteristic-curve (AUC) for binary outcomes and confusion matrices for ternary outcomes.
- the ARI classifier was validated using leave-one-out cross-validation in the same population from which it was derived. Independent, external validation occurred using publically available human gene expression datasets from 328 individuals (GSE6269, GSE42026, GSE40396, GSE20346, and GSE42834). Datasets were chosen if they included at least two clinical groups (bacterial ARI, viral ARI, or non-infectious illness). To match probes across different microarray platforms, each ARI classifier probe was converted to gene symbols, which were used to identify corresponding target microarray probes.
- Clinical decision making is infrequently binary, requiring the simultaneous distinction of multiple diagnostic possibilities.
- the assigned probability represents the extent to which the patient's gene expression response matches that condition's canonical signature. Since each signature intentionally functions independently of the others, the probabilities are not expected to sum to one. To simplify classification, the highest predicted probability determined class assignment. Overall classification accuracy was 87% (238/273 were concordant with adjudicated phenotype).
- Bacterial ARI was identified in 58/70 (83%) patients and excluded 179/191 (94%) without bacterial infection. Viral ARI was identified in 90% (104/115) and excluded in 92% (145/158) of cases. Using the non-infectious illness classifier, infection was excluded in 86% of cases (76/88). Sensitivity analyses was performed for positive and negative predictive values for all three classifiers given that prevalence can vary for numerous reasons including infection type, patient characteristics, or location ( FIG. 8 ). For both bacterial and viral classification, predictive values remained high across a range of prevalence estimates, including those typically found for ARI.
- Procalcitonin a widely used biomarker specific for bacterial infection.
- Procalcitonin concentrations were determined for the 238 subjects where samples were available and compared to ARI classifier performance for this subgroup.
- Procalcitonin correctly classified 186 of 238 patients (78%) compared to 204/238 (86%) using the ARI classifier (p 0.03).
- accuracy for the two strategies varied depending on the classification task. For example, performance was similar in discriminating viral from bacterial ARI.
- Generating classifiers from high dimensional, gene expression data can result in over-fitting.
- the Viral classifier included known anti-viral response categories such as interferon response, T-cell signaling, and RNA processing.
- the Viral classifier had the greatest representation of RNA processing pathways such as KPNB1, which is involved in nuclear transport and is co-opted by viruses for transport of viral proteins and genomes. 26,27 Its downregulation suggests it may play an antiviral role in the host response.
- the Bacterial classifier encompassed the greatest breadth of cellular processes, notably cell cycle regulation, cell growth, and differentiation.
- the Bacterial classifier included genes important in T-, B-, and NK-cell signaling.
- Unique to the Bacterial classifier were genes involved in oxidative stress, and fatty acid and amino acid metabolism, consistent with sepsis-related metabolic perturbations. 28
- Including patients with bacterial and viral infections allows for the distinction between these two states but does not address how to classify non-infectious illness.
- This phenotype is important to include because patients present with infectious and non-infectious etiologies that may share symptoms. That is, symptoms may not provide a clinician with a high degree of diagnostic certainty.
- the current approach which uniquely appreciates the necessity of including the three most likely states for ARI symptoms, can be applied to an undifferentiated clinical population where such a test is in greatest need.
- the small number of discordant classifications occurred may have arisen either from errors in classification or clinical phenotyping. Errors in clinical phenotyping can arise from a failure to identify causative pathogens due to limitations in current microbiological diagnostics. Alternatively, some non-infectious disease processes may in fact be infection-related through mechanisms that have yet to be discovered. Discordant cases were not clearly explained by a unifying variable such as pathogen type, syndrome, or patient characteristic.
- the gene expression classifiers presented herein may be impacted by other factors including patient-specific variables (e.g., treatment, comorbidity, duration of illness); test-specific variables (e.g., sample processing, assay conditions, RNA quality and yield); or as-of-yet unidentified variables.
- patient-specific variables e.g., treatment, comorbidity, duration of illness
- test-specific variables e.g., sample processing, assay conditions, RNA quality and yield
- as-of-yet unidentified variables e.g., unidentified variables.
- the co-identification group was defined by the presence of both bacterial and viral pathogens without further subcategorization as to the likelihood of bacterial or viral disease.
- FIG. 10 is an informative representation of infection status, which could be used by a clinician to diagnose the etiology of ARI.
- Mycoplasma pneumoniae 1 Pasteurella multocida 1 Polymicrobial 11 Pantoea sp.; Coagulase negative Staphylococcus 1 Pseudomonas aeruginosa ; Alcaligenes xylosoxidans 1 Pseudomonas aeruginosa ; Serratia marcescens 1 Staphylococcus aureus ; Haemophilus influenzae 2 Staphylococcus aureus ; Proteus mirabilis 1 Staphylococcus aureus ; Viridans Group Streptococcus; 1 Escherichia coli Streptococcus pneumoniae ; Haemophilus sp.
- Probes selected for the Bacterial ARI, Viral ARI, and Non-infectious Illness Classifiers are presented as Affymetrix probe IDs. Values for each probe represent the weight of each probe in the specified classifier.
- RT-PCR quantitative real-time PCR
- TLDA TaqMan Low Density Array
- TLDA cards will be manufactured with one or more TaqMan primer/probe sets specific for a gene mRNA transcript in the classifier(s) in each well, along with multiple endogenous control RNA targets (primer/probe sets) for data normalization.
- purified total RNA is reverse transcribed into cDNA, loaded into a master well and distributed into each assay well via centrifugation through microfluidic channels.
- TaqMan hydrolysis probes rely on 5′ to 3′ exonuclease activity to cleave the dual-labeled probe during hybridization to complementary target sequence with each amplification round, resulting in fluorescent signal production. In this manner, quantitative detection of the accumulated PCR products in “real-time” is possible. During exponential amplification and detection, the number of PCR cycles at which the fluorescent signal exceeds a detection threshold is the threshold cycle (C t ) or quantification cycle (C q )—as determined by commercial software for the RT-PCR instrument.
- C t threshold cycle
- C q quantification cycle
- the C t for a target RNA is subtracted from the C t of endogenous normalization RNA (or the geometric mean of multiple normalization RNAs), providing a deltaC t value for each RNA target within a sample which indicates relative expression of a target RNA normalized for variability in amount or quality of input sample RNA or cDNA.
- the data for the quantified gene signatures are then processed using a computer and according to the probit classifier described above (equation 1) and reproduce here.
- Normalized gene expression levels of each gene of the signature are the explanatory or independent variables or features used in the classifier, in this example the general form of the classifier is a probit regression formulation:
- ⁇ ( ⁇ ) is the probit link function
- ⁇ 1 , ⁇ 2 , . . . , ⁇ d ⁇ are the coefficients obtained during training
- ⁇ X 1 ,X 2 , . . . , X d ⁇ are the normalized genes expression values of the signature
- d is the size of the signature (number of genes).
- the value of the coefficients for each explanatory variable are specific to the technology platform used to measure the expression of the genes or a subset of genes used in the probit regression model.
- the computer program computes a score, or probability, and compares the score to a threshold value.
- the sensitivity, specificity, and overall accuracy of each classifier is optimized by changing the threshold for classification using receiving operating characteristic (ROC) curves.
- ROC operating characteristic
- the genes of the three signatures that compose the Host Response-ARI (HR-ARI) test were transitioned to a Custom TaqMan® Low Density Array Cards from ThermoFisher Scientific (Waltham, Mass.). Expression of these gene signatures were measured using custom multianalyte quantitative real time PCR (RT-qPCR) assays on the 384-well TaqMan Low Density Array (TLDA; Thermo-Fisher) platform.
- HR-ARI Host Response-ARI
- TLDA cards were designed and manufactured with one or more TaqMan primer/probe sets per well, each representing a specific RNA transcript in the ARI signatures, along with multiple endogenous control RNA targets (TRAP1, PPIB, GAPDH, FPGS, DECR1 and 18S) that are used to normalize for RNA loading and to control for plate-to-plate variability.
- endogenous control RNA targets (TRAP1, PPIB, GAPDH, FPGS, DECR1 and 18S) that are used to normalize for RNA loading and to control for plate-to-plate variability.
- two reference genes out of five available
- primer/probe sets with more than 33% missing values (below limits of quantification) were discarded.
- the remaining missing values are set to 1+max(Cq), where Cq is the quantification cycle for RT-qPCR. Normalized expression values were then calculated as the average of the selected references minus the observed Cq values for any given primer/probe set. See Hellemans et al. (2007) Geno
- 144 primer/probe sets measure gene targets representative of the 132 previously described Affymetrix (microarray) probes of the three ARI gene signatures (i.e., the genes in the bacterial gene expression signature, the viral gene expression signature and the non-infectious gene expression signature); 6 probe sets are for reference genes, and we additionally assayed 24 probe sets from a previously-discovered pan-viral gene signature. See U.S. Pat. No. 8,821,876; Zaas et al. Cell Host Microbe (2009) 6(3):207-217.
- RNA was purified from PAXgene Blood RNA tubes (PreAnalytix) and reverse transcribed into cDNA using the Superscript VILO cDNA synthesis kit (Thermo-Fisher) according to the manufacturer's recommended protocol.
- a standard amount of cDNA for each sample was loaded per master well, and distributed into each TaqMan assay well via centrifugation through microfluidic channels.
- the TaqMan hydrolysis probes rely on 5′ to 3′ exonuclease activity to cleave the dual-labeled probe during hybridization to complementary target sequence with each amplification round, resulting in fluorescent signal production.
- Quantitative detection of the fluorescence indicates accumulated PCR products in “real-time.”
- the number of PCR cycles at which the fluorescent signal exceeds a detection threshold is the threshold cycle (C t ) or quantification cycle (C q )—as determined by commercial software for the RT-qPCR instrument.
- Non-infectious illness was defined by the presence of SIRS criteria, which includes at least two of the following four features; Temperature ⁇ 36° or >38° C.; Heart rate >90 beats per minute; Respiratory rate >20 breaths per minute or arterial partial pressure of CO 2 ⁇ 32 mmHg; and white blood cell count ⁇ 4000 or >12,000 cells/mm 3 or >10% band form neutrophils.
- SIRS criteria includes at least two of the following four features; Temperature ⁇ 36° or >38° C.; Heart rate >90 beats per minute; Respiratory rate >20 breaths per minute or arterial partial pressure of CO 2 ⁇ 32 mmHg; and white blood cell count ⁇ 4000 or >12,000 cells/mm 3 or >10% band form neutrophils.
- Three subjects did not report ethnicity. M, Male. F, Female. B, Black. W, White, O, Other/Unknown.
- GSE numbers refer to NCBI Gene Expression Omnibus datasets. N/A, Not available based on published data.
- bacterial ARI vs. viral ARI and non-infectious illness
- viral ARI vs. bacterial ARI and non-infectious illness
- non-infectious illness vs. bacterial and viral ARI.
- the thresholds for each of the classifiers are selected from Receiving Operating Characteristic (ROC) curves using a symmetric cost function (expected sensitivity and specificity are approximately equal) (Fawcett (2006) Pattern Recogn Lett 27:861-874).
- a subject is predicted as bacterial ARI if p(bacterial ARI)>t b , where t b is the threshold for the bacterial ARI classifier.
- t b is the threshold for the viral ARI classifier.
- t v and t n are the thresholds for the viral ARI and non-infectious illness classifiers.
- a combined prediction can be made by selecting the most likely condition, i.e., the one with largest probability, specifically we write, argmax ⁇ p(bacterial ARI),p(viral ARI),p(non-infectious illness) ⁇ .
- the model yielded bacterial ARI, viral ARI, and non-infectious illness accuracies of 80% (24 correct of 30), 77.4% (24 correct of 31) and 85.3% (29 correct of 34), respectively.
- area under the ROC curves 0.92, 0.86 and 0.91, for the bacterial ARI, viral ARI and non-infectious illness classifier, respectively.
- the weights and thresholds for each of the classifiers are shown in the Table 12, shown below. Note that this Table lists 151 gene targets instead of 174 gene targets because the reference genes were removed in the preprocessing stage, as described above, as were 17 targets for which there were missing values. These 17 targets were also removed during the preprocessing stage.
- panviral signature genes are removed, we see a slight decreased performance, no larger than 5% across AUC, accuracies and percent of agreement values.
- the composite host-response ARI classifier is composed of gene expression signatures that are diagnostic of bacterial ARI versus viral ARI, versus non-infectious illness and a mathematical classification framework.
- the mathematical classifiers provide three discrete probabilities: that a subject has a bacterial ARI, viral ARI, or non-infectious illness. In each case, a cutoff or threshold may be specified above which threshold one would determine that a patient has the condition. In addition, one may modify the threshold to alter the sensitive and specificity of the test.
- the measurement of these gene expression levels can occur on a variety of technical platforms.
- the mathematical framework that determines ARI etiology probabilities is adapted to the platform by platform-specific training to accommodate transcript measurement methods (i.e., establishing platform-specific weights, w 1 , . . . , w p ). Similar, straightforward, methodology could be conducted to translate the gene signatures to other gene expression detection platforms, and then train the associated classifiers.
- This Example also demonstrates good concordance between TLDA-based and microarray-based classification of etiology of ARI.
- TLDA Assay ID Bacterial Viral Non-infectious Group Gene Symbol RefSeq ID Gene Name Hs00153304_m1 0.44206 ⁇ 0.19499 0 CD44 NM_000610.3; NM_001202555.1; hCG1811182 Celera Annotation; CD44 molecule (Indian blood NM_001001392.1; NM_001202556.1; group) NM_001001391.1; NM_001001390.1; NM_001001389.1 Hs00155778_m1 0 0 0 APLP2 NM_001142278.1; NM_001142277.1; hCG2032871 Celera Annotation; amyloid beta (A4) precursor-like NM_001142276.1; NR_024515.1; protein 2 NR_024516.1; NM_001642.2; NM_
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/738,339 US20180245154A1 (en) | 2015-07-01 | 2016-06-30 | Methods to diagnose and treat acute respiratory infections |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187683P | 2015-07-01 | 2015-07-01 | |
US201562257406P | 2015-11-19 | 2015-11-19 | |
US15/738,339 US20180245154A1 (en) | 2015-07-01 | 2016-06-30 | Methods to diagnose and treat acute respiratory infections |
PCT/US2016/040437 WO2017004390A1 (en) | 2015-07-01 | 2016-06-30 | Methods to diagnose and treat acute respiratory infections |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180245154A1 true US20180245154A1 (en) | 2018-08-30 |
Family
ID=57609334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/738,339 Abandoned US20180245154A1 (en) | 2015-07-01 | 2016-06-30 | Methods to diagnose and treat acute respiratory infections |
Country Status (7)
Country | Link |
---|---|
US (1) | US20180245154A1 (ja) |
EP (2) | EP3316875B1 (ja) |
JP (3) | JP7002037B2 (ja) |
CN (1) | CN107847464A (ja) |
AU (2) | AU2016288208A1 (ja) |
CA (1) | CA2989199A1 (ja) |
WO (1) | WO2017004390A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210230694A1 (en) * | 2018-06-05 | 2021-07-29 | University Of Rochester | Nasal genes used to identify, characterize, and diagnose viral respiratory infections |
US20210302425A1 (en) * | 2020-03-26 | 2021-09-30 | Deborah Ann Payne | Methods for detecting the presence of bacteria, fungi, parasites, and viruses in a test sample and treating a patient |
WO2021252864A1 (en) * | 2020-06-11 | 2021-12-16 | Duke University | Methods to detect and treat sars-cov-2 (covid19) infection |
US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
WO2022235765A3 (en) * | 2021-05-04 | 2023-01-05 | Inflammatix, Inc. | Systems and methods for assessing a bacterial or viral status of a sample |
WO2023086827A1 (en) * | 2021-11-09 | 2023-05-19 | Rhode Island Hospital | Predicting covid-19 antibodies among survivors with deep rna sequencing |
WO2023091970A1 (en) * | 2021-11-16 | 2023-05-25 | The General Hospital Corporation | Live-cell label-free prediction of single-cell omics profiles by microscopy |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018140256A1 (en) * | 2017-01-17 | 2018-08-02 | Duke University | Gene expression signatures useful to predict or diagnose sepsis and methods of using the same |
US20190376969A1 (en) * | 2017-02-03 | 2019-12-12 | Duke University | Nasopharyngeal protein biomarkers of acute respiratory virus infection and methods of using same |
GB201703036D0 (en) * | 2017-02-24 | 2017-04-12 | Hvivo Services Ltd | Methods |
EP3655549B1 (en) * | 2017-07-21 | 2023-01-04 | BioFire Diagnostics, LLC | Detection using concurrent melting curves |
WO2019217296A1 (en) * | 2018-05-07 | 2019-11-14 | Yale University | Test to distinguish viral-only from bacterial infection or viral/bacterial coinfection using a respiratory swab |
EP3608912A1 (de) * | 2018-08-06 | 2020-02-12 | Siemens Healthcare GmbH | Ermitteln einer substanzklasse eines nosokomialen keims |
CN111048200A (zh) * | 2019-11-25 | 2020-04-21 | 上海交通大学 | 一种自闭症患者刻板行为评估系统、方法及终端 |
GB202107883D0 (en) * | 2021-06-02 | 2021-07-14 | Orph Pharma Ip Company Ltd | Biomarkers and method for classifying subjects following viral exposure |
JP7235909B1 (ja) | 2022-03-16 | 2023-03-08 | 川崎重工業株式会社 | 検査支援装置 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050209785A1 (en) * | 2004-02-27 | 2005-09-22 | Wells Martin D | Systems and methods for disease diagnosis |
CA2695935A1 (en) * | 2006-08-11 | 2008-02-28 | Baylor Research Institute | Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections |
EP2405806A4 (en) * | 2009-03-10 | 2014-01-22 | Univ Duke | PREDICTION OF CORONARY DISEASE AND THE RISK OF CARDIOVASCULAR EVENTS |
US20120077767A1 (en) | 2009-05-26 | 2012-03-29 | Zaas Aimee K | Molecular predictors of fungal infection |
CN103119444B (zh) | 2010-04-21 | 2016-10-26 | 米密德诊断学有限公司 | 区分细菌与病毒感染的标记物和决定因素以及其使用方法 |
EA201590175A1 (ru) | 2012-07-26 | 2015-06-30 | Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния | Скрининг, диагностика и прогнозирование аутизма и других нарушений развития |
EP2914740B1 (en) | 2012-10-30 | 2017-09-13 | Imperial Innovations Ltd | Method of detecting active tuberculosis in children in the presence of a co-morbidity |
US10689701B2 (en) | 2013-03-15 | 2020-06-23 | Duke University | Biomarkers for the molecular classification of bacterial infection |
WO2015048098A1 (en) * | 2013-09-24 | 2015-04-02 | Washington University | Diagnostic methods for infectious disease using endogenous gene expression |
-
2016
- 2016-06-30 JP JP2017568212A patent/JP7002037B2/ja active Active
- 2016-06-30 WO PCT/US2016/040437 patent/WO2017004390A1/en active Application Filing
- 2016-06-30 US US15/738,339 patent/US20180245154A1/en not_active Abandoned
- 2016-06-30 CN CN201680038489.9A patent/CN107847464A/zh active Pending
- 2016-06-30 EP EP16818801.9A patent/EP3316875B1/en active Active
- 2016-06-30 CA CA2989199A patent/CA2989199A1/en active Pending
- 2016-06-30 AU AU2016288208A patent/AU2016288208A1/en not_active Abandoned
- 2016-06-30 EP EP21207860.4A patent/EP3974539A1/en active Pending
-
2021
- 2021-08-23 JP JP2021135662A patent/JP2021192620A/ja active Pending
- 2021-10-19 AU AU2021254546A patent/AU2021254546B2/en active Active
-
2023
- 2023-08-21 JP JP2023134150A patent/JP2023179410A/ja active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210230694A1 (en) * | 2018-06-05 | 2021-07-29 | University Of Rochester | Nasal genes used to identify, characterize, and diagnose viral respiratory infections |
US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
US11468355B2 (en) | 2019-03-04 | 2022-10-11 | Iocurrents, Inc. | Data compression and communication using machine learning |
US20210302425A1 (en) * | 2020-03-26 | 2021-09-30 | Deborah Ann Payne | Methods for detecting the presence of bacteria, fungi, parasites, and viruses in a test sample and treating a patient |
WO2021252864A1 (en) * | 2020-06-11 | 2021-12-16 | Duke University | Methods to detect and treat sars-cov-2 (covid19) infection |
WO2022235765A3 (en) * | 2021-05-04 | 2023-01-05 | Inflammatix, Inc. | Systems and methods for assessing a bacterial or viral status of a sample |
WO2023086827A1 (en) * | 2021-11-09 | 2023-05-19 | Rhode Island Hospital | Predicting covid-19 antibodies among survivors with deep rna sequencing |
WO2023091970A1 (en) * | 2021-11-16 | 2023-05-25 | The General Hospital Corporation | Live-cell label-free prediction of single-cell omics profiles by microscopy |
Also Published As
Publication number | Publication date |
---|---|
AU2016288208A1 (en) | 2018-02-22 |
AU2021254546A1 (en) | 2021-11-18 |
CA2989199A1 (en) | 2017-01-05 |
JP2018523998A (ja) | 2018-08-30 |
JP7002037B2 (ja) | 2022-02-04 |
EP3316875A1 (en) | 2018-05-09 |
CN107847464A (zh) | 2018-03-27 |
EP3316875B1 (en) | 2021-11-17 |
EP3316875A4 (en) | 2018-12-26 |
EP3974539A1 (en) | 2022-03-30 |
AU2021254546B2 (en) | 2023-11-16 |
JP2023179410A (ja) | 2023-12-19 |
JP2021192620A (ja) | 2021-12-23 |
WO2017004390A1 (en) | 2017-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3316875B1 (en) | Methods to diagnose acute respiratory infections | |
US20220325348A1 (en) | Biomarker signature method, and apparatus and kits therefor | |
US20230045305A1 (en) | Rna determinants for distinguishing between bacterial and viral infections | |
EP3362579B1 (en) | Methods for diagnosis of tuberculosis | |
JP2023098945A (ja) | 細菌感染及びウイルス感染を診断するための方法 | |
US20110183856A1 (en) | Diagnosis and Prognosis of Infectious Disease Clinical Phenotypes and other Physiologic States Using Host Gene Expression Biomarkers In Blood | |
US20150315643A1 (en) | Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis | |
US20220251647A1 (en) | Gene expression signatures useful to predict or diagnose sepsis and methods of using the same | |
Hermann et al. | Diagnostic potential of circulating cell‐free microRNAs for community‐acquired pneumonia and pneumonia‐related sepsis | |
JP2022153436A (ja) | 重篤患者における死亡率の予後診断に使用するためのバイオマーカー | |
US20150011415A1 (en) | Method for calculating a disease risk score | |
US20220399116A1 (en) | Systems and methods for assessing a bacterial or viral status of a sample | |
KR20210070976A (ko) | 가와사키병을 갖는 대상체를 확인하는 방법 | |
EP3825418A2 (en) | Molecular signatures for distinguishing liver transplant rejections or injuries | |
US11739369B2 (en) | Immune profiling using small volume blood samples | |
EP4352250A1 (en) | Diagnostic for sepsis endotypes and/or severity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DUKE UNIVERSITY, NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TSALIK, EPHRAIM L.;GIRALDO, RICARDO HENAO;BURKE, THOMAS W.;AND OTHERS;SIGNING DATES FROM 20180309 TO 20180514;REEL/FRAME:045808/0795 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION COUNTED, NOT YET MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |